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ABSTRACT 
We have cloned and sequenced the aroA gene of Pasteurefla haemo~vtica serotype (ST) 2, 
the principal etiologic agent of pneumonic pasteurellosis of sheep. The aroA gene is 1,296 
nucleotides long, has a %G+C content of 42%, and encodes a polypeptide of 432 amino 
acids. The P. haemo~vtica ST 2 AroA protein has a deduced molecular weight of 47,070 
daltons and an isoelectric point of 4.88. In addition, we have constructed an aroA mutant of 
P. haemolytica ST 2 and demonstrated its diminished ability to grow in Wessman defined 
media lacking the amino acid tryptophan. Previous studies utilizing avirulent aroA mutants 
of the Pasteurella spp. have shown promise as live attenuated vaccine candidates in cattle. 
We hope to use this mutant in future research as a vaccine candidate again t pneumonic 
pa teurellosis in sheep. Furthermore, incorporation of this mutant as part of a multivalent 
vacc ine containing aroA mutants of P. haemo~vtica A I and P. multocida A3 as well as 
Haemophilus somnus may be des irable for increased control of pasteurellosis in cattle. 
GENERAL I NTRODUCTION 
Hypothesis and Rational 
Pasteurella haemolytica is a prominent pathogen of ruminant species uch as cattle and 
sheep (25, 98). It is estimated that the loss to the North American cattle industry due to this 
pathogen is between £750 million to $4 billion annually (98, 71 ). ln the United States, 
Bighorn Sheep are the latest to succumb to both the pneumonic and septicemic fonns of 
pasteurellosis (98). In the United Kingdom, pasteurellosis of sheep is also a serious economic 
problem (39). Moreover, due to the questionable efficacy of current vaccination programs, 
this disease still poses a threat to the cattl e and sheep industries (34, 39). 
Pasteurella haemo(vtica serotype (ST) 2 is the predominant etiologic agent of pneumonic 
pa teurellos is of lambs and sheep (39). It is a commensal of the upper respiratory tract and 
tonsils of both sheep and cattle (I 0, 34, 98). During periods of stress, bacterial or viral 
infection, c limate changes, and seasonal changes, outbreaks of pasteurellosis are often 
observed ( I 0, 34, 39, 98). The spread of Pasteurella through a flock of sheep is not always 
unifonn and researchers are not sure as to the primary mechanism of pathogenesis or 
infectious spread. ln cattle, however, the speculation is that aerosolized particles from P. 
haemo~\·tica ST I infected calves are inspired by neighboring calves (34). In animals 
experiencing stress, the pathogen proliferates on upper resp iratory tract mucosa! surfaces 
(34). Colonization of these mucosa! surfaces by P. haemo~vtica results in no adverse clin ical 
effects except transient fever, but is presumed to be a necessary precursor to the development 
of pneumonia. 
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The use of li ve attenuated pathogens as vaccines has been well studied. In the 1950s, 
Bacon demonstrated attenuation of Salmonella typhi by disruption of the aromatic amino acid 
biosynthetic pathway (6). During infect ion, the S. typhi mutant exhibited a diminished ability 
to grow yet rema ined immunogenic (6, 12, 2 1, 27, 44-46, 7 1, 92, 93). Further studies yielded 
information about the aromatic amino acid biosynthetic pathway of which the aroA gene 
product, 5-enolpyruvylshikimate 3-phosphate synthase is a critical enzyme. This pathway 
yields the amino acids tryptophan, tyrosine, and phenylalanine as well as folate, vitamin K , 
and 2,3-dihydroxybenzoate (38, I 0 I). Many studies have utilized aroA mutants as a virulent 
attenuated li ve vaccine candidates. For example, pathogens such as Salmonella typhimurium 
(46), Salmonella enteritidis (27), Shigellajlexneri (93), Yersinia enterocolitica ( 12), Yersinia 
pestis (70), Neisseria gonorrhoeae (2 1 ), Pasteurella multocida (44), and Pasteurella 
haemo~vtica ST I ( 45) were shown to be attenuated when the aroA gene was mutated. 
Moreover, further experiments have demonstrated that they were good li ve vacc ine 
candidates. Based on these examples, the goal of this study was to c lone, sequence and 
construct an aroA mutant of P. haemo~vtica ST 2 for use as an attenuated live vaccine 
candidate to protect against pneumonic pasteurellosis in sheep. 
Thesis Organization 
This thesis is organized in a standard format consisting of four chapters, a General 
Introduction with Literature Review, Materials and Methods, Results and Discussion and 
Conc lus ions. This thesi s follows the convention of the American Society for Microbiology. 
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Literature Review 
In the early days of bacterio logy the only criteria fo r classify ing bacteria were their 
microscopic and cultural morpho logical feature and the circumstances. loyalties or 
personalities associated with thei r first recognition. 
- K. Zinneman, 1980 
General history 
The hi story of Pasteurella spp. is vast. Much of the early classi fi cation of this group of 
bacteria was based on three criteria: the animal that was infected. biochemica l react ions and 
serological reactions (33, 76). The latter two were often contradictory therefore, on many 
occas ions the names or classifications of Pasteurelfa spp. were changed to fit new, emerging 
criteria and ideology (33, 76). 
As early as the 1600s. before the advanced techniques of bacterial iso lat ion and 
identification had been developed, Androvandus of Italy had reported an ep izootic di sease of 
fowls that proved to be deadly. This seems to be the earliest report of what was later called 
fowl cholera (76). In the 1880s, Toussaint was the first to iso late and describe P. multocida 
fro m blood, culti vate it in neutralized urine and prove that it was the causative agent of fowl 
cholera (76) . 
It was, however, Louis Pasteur who isolated and cultivated P. multocida in pure cultures 
using chicken broth in the 1880s (76). He studied the many aspects of this organism and was 
able to show that an attenuated fo rm of the bacteria protected chickens fro m subsequent 
infections with the parenta l strain. From his work came three important bio logical princ iples: 
1) recovery from infection would protect against subsequent challenge, 2) attenuation of the 
organism would affect virulence, and 3) immunity would be overwhelmed by a large 
challenge dose (1 7, 52). 
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Pasteurellosis of sheep was first described in 1923 by Spray where he reported a non-
septicemic form of pneumonia in lambs at slaughter (33). Upon examination of diseased 
lamb lungs varying areas of consolidation or hepatization were observed. Furthermore Spray 
isolated Pasteurella-like organisms associated with the pneumonic lesions and demonstrated 
a narrow ring of partial hemolysis on culture. In 1931, Dungal reported an outbreak of 
pneumonia in housed sheep. He reproduced the disease by inoculating healthy sheep 
intratracheally with cultivated organisms collected from infected sheep (39). Although there 
is skepticism based on his description of the causal organism, there seems to be little doubt 
that Dungal was describing P. haemolytica (39). The first observation that clinical symptoms 
may be induced by stress was described in 1938 by Montgomerie et al. (39). They noticed 
that rapid environmental changes such as climate precipitated outbreaks of pneumonia in 
sheep. In 1955 the septicemic form of the disease was first described in the South of 
Scottland by Stamp et al. (39). There they reported a rapidly fatal disease of lambs and 
found the causitive agent to be P. haemolytica. 
Taxonomy of the family Pasteurellaceae 
The family Pasteurellaceae includes a wide variety of Gram negative, facultatively 
anaerobic, chemoorganotrophic, and fermentative bacteria (67). Table 1 lists some common 
features of the family Pasteurellaceae ( 67). Based on phenotypic and genetic analysis, 
approximately twenty different species of Pasteurella have been identified (25). The 
Pasteurella spp. are differentiated on the basis of beta hemolysis, growth on MacConkey's 
agar, indole production, urease activity, gas from carbohydrates, acid production from lactose 
or mannitol, and 2-dimensional protein electrophoresis ( 19, 69, 100). However, due to the 
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Table I. Some common features of the family Pasteurellaceae 
Small Gram-negative rods or coccobacilli 
Facultatively anaerobic or microaerophi lic 
Growth temperature 
Motility 
Spores 
Oxidase and/or alkaline phosphatase 
Glucose catabolism (0-F test) 
Nitrate reduction 
Simmon 'citrate (growth) 
Arginine dihydrolase 
Adonitol 
L-Sorbose 
*Exceptions: H.aegyprius. H. ducreyi 
30°C-40°C 
+ 
F* 
+ 
Adapted from : Muuers. R., Mannheim. W., Bisgaard. M .. 1989. Taxonomy of the group, In: C. Adlam and 
J.M. Rutter (Editors), Pasreurella and Pasreure/losis. Academic Press. London, pp. 3-34. 
problems inherent with classifying genera based on phenotypic properties alone, i.e., 
incomplete expression of the genome, techniques such as DNA/DNA hybridization (66) and 
rRNA analysis (28) are used to help establish taxonomic relationships. 
Pasteurella haemolytica was first described in 1921 by Jones and referred to as 
Pasteure//a boviseptica group I by Lingieres in his zoological classification of the 
Pasteurella spp. (33). However, as identification of infectious organisms improved, it 
became c lear that the classification of bovine and ovine isolates of the family 
Pasteurel/aceae into one species, P. boviseptica, was not sufficient. Lingieres thought that 
the family should be broken up into host specific groups such as P. avicida (fowl), P. 
boviseptica (cattle) P suiseptica (swine), and P. oviseptica (ovine) (66, 67). Furthermore, in 
1932, ewsome and Cross separated P. haemo/ytica from P. multocida giving rise to the two 
independent species of the Pasteurellae (52 , 66, 67). 
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The taxonomy of the Pasteurelfaceae has undergone several modifications as 
classification techniques have become more precise based on new technologies. Through the 
use of techniques such as capsular antigen typing and ON A/ON A hybridization many of the 
members of this vast family of organisms have been reclassified or eliminated. For example, 
a new classification scheme has excluded several traditional species from P. sensu stricto 
including P. haemolytica, and rRNA evidence has even brought into question their 
classification as Pasteurella (25, 28). Table 2 illustrates the taxa eliminated from the family 
Pasteurellaceae as of 1989 (67) . 
Table 2. Taxa eliminated from the family Pasteurelfaceae 
Previous designation New description or location 
Haemophilus equigenitalis Tay/ore/la equigenitalis 
rRNA superfamily III 
H. piscium Genus Aeromonas 
H. vagina/is Gardnerella vagina/is 
Morazella (Pasteurella) anatipestifer Flavobacterium/Cytophaga group 
Pasteurelfa-like Bovine-
lymphangitis group 
P. piscicida 
Pasteurelfa-1ike CDC group EF-4 
Enterobacteriaceae 
Vibrionaceae 
rRNA superfamily III 
Criteria used 
Phenotype 
Ribosomal cistrons 
Phenotype 
Phenotype 
DNA binding 
Ribosomal cistrons 
Ribosomal cistrons 
Ribosomal cistrons 
Adapted from: Mutters, R. , Mannheim, W., Bisgaard, M., 1989 . Taxonomy of the g roup, In: C. Adlam and 
J.M. Rutter (Ed itors). Pasteurella and Pasteurellosis. Academic Press. London, pp. 3-34 
Currently, Pasteurella haemoly tica is classified under the family Pasteurella Pohl 1981 
on the basis of genetic relatedness to the other members of this family as determined by DNA 
renaturation (67). This family consists of what's known as the HAP complex of organisms 
which are the genera Haemophilus, Actinobacillus, and Pasteurella. These organisms 
encompass a wide tropism of hosts but share genetic, phenotypic, and to some extent, 
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pathologic similarities. For example, hosts of the HAP complex include most mammals such 
as man, cattl e, sheep, pigs, dogs, rats, mice, and various birds including chickens and pigeons 
(67). Moreover, the pathology can be pneumonic or septicemic with preference for mucosa! 
surfaces (67). A thorough review of the HAP complex is beyond the scope of this paper. 
Therefore, the reader is referred to reference 67 for an in-depth discuss ion of the genera 
Haemophi/us and Actinobaciflus. 
Pasteurella haemolytica 
P. haemo~vtica has been divided into two groups based on fermentation of the sugars 
trehalose and arabinose. The former comprise the T biotypes whereas the latter comprise the 
A biotypes. Recently, however, a move has been made toward reclassifying the T biotypes 
into a separate species, P. trehalosi (25). P. haemo~vtica can be further typed according to 
capsular antigens. ix teen serotypes ( 12 are biotype A and 4 are biotype T) have been 
distinguished by indirect hemagglutination developed by Biberste in (4, 34) or rapid plate 
agglutination developed by Frank (34, 36). Biotype A consists of serotypes I, 2, 5, 6, 7, 8, 9, 
11 , 12, 13, 14, and 16. Biotype T inc ludes serotypes 3, 4, I 0, and 15 (34). Moreover, many 
strains fall into an ' untypable' category. Indirect hemagg lutination of these untypable strains 
fails, presumably due to a lack of so luble antigen. They can be subgrouped by the rapid plate 
agglutination procedure, however (34). The disease produced by the A biotypes and the T 
biotypes are markedly different, and only the A biotypes are the causitive agents of the 
pneumonic form of the d isease. 
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Pasteurellosis: the disease 
P. haemo(vtica and P. multocida are the most prominent pathogens in domestic animals 
causing severe diseases and major economic losses to the cattle, swine, sheep and poultry 
industries. It has been estimated that the cost to the North American cattle industry ranges 
fro m $750 million to $4 billion annually (71 , 98). Recently, P. haemo(vtica has been 
identified in the Rocky Mountain bighorn sheep population resulting in a Joss of bighorn 
sheep due to the pneumonic and septicemic forms of pasteurellosis (98). Moreover, 
Pasteurella is not an iso lated problem to North America. As recently as 199 1, Bloch 
conducted a serosurvey on 1,474 small ruminants in four districts of Niger ( 11 ). Of eight 
diseases studied, pasteure llosis was found to be the main health problem ( 11 ). Therefore, 
efforts to control the progression and propagation of pasteurellosis have been of importance 
to researchers. A full understanding of the pathology of these organisms and their host 
preference is critica l to a successfu l eradication program. 
Pasteurella haemo/ytica is a member of the HAP complex of pathogens, which infect a 
wide variety of hosts. Many of the diseases produced by these organisms are assoc iated with 
the upper respiratory tract (URT) or the lower genital tract (LGT) (73). The HAP complex of 
diseases are characterized by (i) the clinical symptoms manifested, (ii) the host infec ted, (i ii) 
and the serogroup and/or serotype iso lated from the site of infection (99). Diseases produced 
by the HAP complex have been placed into three categories based on clinical symptoms: I) 
Pneumonia/septicemia which inc lude: hemorrhagic septicemia of cattle, P. multocida; fowl 
cholera of turkeys, water fowl, etc., P. multocida; septicemic pasteurellosis of lambs and 
goats, P. haemolytica; pasteurellosis of rabbits, P. multocida; shipping fever of cattle, P. 
haemolytica, P. multocida, H. somnus; enzootic pneumonia of sheep. P. haemolytica . 2) 
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Upper respiratory infections which include: infectious coryza, conjunctivit is, sinusitis of 
chickens and other fowl, H. (para)gallinarum; atrophic rhinitus of swine, P. multocida; and 
conjuncti vitis of humans, Haemopliilus spp. 3) Local/traumatic infection which include: 
In fected bite wounds of humans and carnivores, P. multocida, P. dagmatis, P. stomal is, P. 
canis; serosal empyemas (e.g. pyothorax) of cats and dogs, P. multocida and others; 
periodontal disease of humans, Actinobacillus actinom\'cetecomitans; subcutaneous 
granulomas of cattle, P. granulomatis; and cervicovaginitis of cattle, H. somnus (73). This 
list illustrates the wide range of hosts the HAP complex infects and underscores a common 
attraction for mucosa! surfaces. 
Pasteurella spp. survive as commensals on the mucus membrane of the URT and LGT 
of healthy animals. P. haemolytica ST2 , and to a lesser extent ST I, can be recovered from 
healthy cattle, however, in calves that show clinical manifestations of pneumonic 
pasteurellosis, ST I is almost exclusively recovered from the lung (34, 39). Sheep shed and 
succumb to a number of serotypes of P. haemo~vtica, although serotype 2 is most often 
recovered from pneumonic lung (I 0, 34, 39, 67). In catt le and sheep, c linical infection with 
P. haemo~vtica is commonly characterized as an acute, fulminating, fibrinonecrotic 
pleuropneumonic infection of the respiratory tract most frequently associated with "shipping 
fever" (34). The stress associated with the movement of cattl e to feedlots allows Pasteurellae 
to proliferate in the URT by an unknown mechanism and spread to the lower respiratory tract 
(LRT) where colonization of the lung occurs. Much focus has been spent on elucidating the 
mechanism of passage of P. haemolytica from the URT to the LRT where clinical pneumonia 
results ( 41 ). The diagram in Figure I shows the steps invo lved in infection of a host by 
members of the HAP complex (81 ). 
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Predisposing Factors: 
stress, transport, virus, Mycoplasma 
J. 
Decrease mucociliary clearance, 
impaired alveolar macrophage function 
J. 
Proliferation and inhalation 
of nasopharyngeal Pasteurellae, 
colonization of the lung 
J. 
Release of toxins, other virulence factors 
J. 
Mast cell degranulation, complement activation, 
infiltration and lysis of neutrophils and macrophages; 
J. 
Fibrinous or purulent pneumonia 
Figure I. Flow chart of the steps of pasteurellosis infection. 
It has been hypothesized that several factors may be involved in mucosa! colonization of 
P. haemolytica including fimbriae, P. haemolytica A I serotype-specific agglutination antigen 
(PHA J SSA), polysaccharide capsule (glycocalyx), lipopolysaccharide (LPS), neuraminidase 
and glycoprotease. Some of these factors directly associate with host cell membranes 
whereas others modify the microenvironment to promote proliferation of the pathogen. P. 
haemolytica colonizes the lung and evades the host immune response by secreting enzymes 
and toxins (discussed below). Moreover, capsule, capsular antigens, cytotoxins and 
lipopolysaccharides prevent the host immune system from mounting an effective attack 
against the invading pathogen. For example, the capsule is biologically inert, and therefore, 
has a low affinity for opsonization and fixation of immune modulators to the bacterial cell 
membrane, e.g. nonspecific antibody and C3b of the complement cascade respectively. 
1 I 
To more fully understand the disease progression of P. haemozvtica and to develop 
strategies to el iminate this pathogen, knowledge of its viru lence factors and metabo lic 
pathways are required . For example, it is understood that the Pasteurellae share many of 
their virulence factors. There are exceptions, however, and perhaps these exceptions allow 
for the host specificity found with each species. An example of thi s idea is demonstrated 
between P. haemozvtica and P. multocida. These two organisms present a relatively similar 
mucoid morphology when cultured on blood agar media containing 5% bovine erythrocytes 
(34). However, the clinical disease often described for each species is different; a fi brinous 
disease is usually seen with P. haemolytica where a purulent pneumonia is normally 
associated with P. multocida (34, 77). Both species use the capsular polysaccharide fo r 
protection against the host immune response, while each species produces di fferent toxins, 
i.e. leukotoxin and dermonecrotic toxin, respectively, that aid in tissue damage (34, 77). 
Therefore, a better understanding of the imrnunogens of P. haemozvtica and eluc idation of 
mechanisms involved in mucosa! colonization and destruction of host tissues may aid in the 
design of vaccines to protect cattle and sheep from clinica l infection with this pathogen. 
I mmunogens of Pasteurella haemolytica 
Prokaryotes have evolved mechanisms that allow them to surv ive in specific hosts. For 
example, facultat ive gram negative bacteria like Salmonella, Brucella and Mycobacterium 
have deve loped the ability to survive intracellularly in macrophages and neutrophi ls after 
release from the phagolysosomal vacuole (I 00). Other gram negative bacteria, for example 
Escherichia coli, can survive through mimicry of host proteins on their cell surface or 
antigenic shift of cell membrane proteins ( I 00). Sti ll others, such as members of the family 
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Pasteure/laceae, produce toxins that can kill host tissues or immune cells ( 4, I 0, 34). Many 
pathogenic bacteria utilize a combination of these factors in order to aid their survival within 
the host. The viru lence factors associated with P. haemolytica that may play a role in 
pathogenesis are the adhesins, capsule (glycocalyx), LPS, cytotoxin (exotoxin), and secreted 
enzymes such as neuraminidase or glycoprotease. The list is not comprehensive, but it 
includes some of the more important virulence factors that contribute to colonization and 
pathogenesis of the respiratory tract. 
Adhesins 
Adhesins are cell associated moieties or appendages that facilitate attachment to host cells 
via a cell surface receptor interaction (26). This interaction is important in establishing 
colonization and allowing microcolony formation. These attached colonies resist host 
clearance mechanisms such as the mucociliary escalator, and gain a valuable advantage over 
the host defenses. This advantage may be one of the key points in the pathogenesis of P. 
haemo/ytica in the ruminant respiratory tract (26). The most common adhesins of 
prokaryotes are fimbriae or pili which are small filamentous appendages on the surface of 
bacterial cells. Their role in infection is thought to be one of adherence to mucosa) surfaces 
in the initial stages of infection (62). In addition to fimbriae however, Gram negative 
pathogens express adhesive factors that are often distinct and independent from fimbriae or 
pili. For example, Bordatella pertussis utilizes a filamentous hemagglutinin to colonize the 
upper respiratory tract (72). The main adhesin uti lized by Bordatella bronchiseptica is the 
bovine erythrocyte hemagglutinin (72). In both of these examples the presence of fimbriae 
does not appear critical for adhesion to cell surfaces. 
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In the late 1980s, Morck et al. demonstrated capsule and fi mbri ae were present on P. 
haemo(vtica iso lated from cattle showing c linical signs of pneumonic pasteurellosis (64). 
Typical P. haemozwica cells were evident w ith clearly visible radial g lycocalyces suggesting 
the presence o f fimbriae. Two types of fimbriae were identified, a large 12 nm rigid structure 
and a smaller 5 nm more flexible structure. Furthermore, Potter et al., have reported iso lation 
and purification of fimbrial subuni ts, although several laboratories have fai led to repeat these 
fi nd ings us ing the same techniques (74). The presence of fimb riae in P. haemolytica has not 
been investigated full y, nor have their ex istence been confirmed by other investigators (26). 
The serotype-specifi c capsular antigen of P. haemoz\·tica A 1, PHA 1 SSA. was c loned and 
described as a fimbrial structural un it by Lo et al. (58). lmmunoelectron microscopy stud ies 
of the cloned PHA l SSA confirmed its cell surface location, but fa iled to reveal a cellular 
morpho logy cons istent with the presence of ft mbrial structures ( 41 ). The role of PHA I SSA 
in the pathogenesis of P. haemozvtica is still uncerta in, however, Gonzalez et al. speculate 
that the ST l -spec ific agglutinating antigen could promote adhesion of the pathogen to host 
tissues through a lectin binding interaction with cell surface molecules ( 41 ). 
Capsule 
The capsule (glycocalyx) of P. haemo(vrica is composed of polyanionic, acidic, high 
mo lecular weight, heterogeneous polysaccharides, which are useful in serotyping (49). 
Encapsulated stra ins are thought to be more pathogenic, although the presence of a capsule 
does not always correlate with virul ence (68). Non-encapsulated isogenic mutants of other 
species are generally a virulent and are quickly removed from the host ( 49). Bacterial capsule 
has been purified and found to be both biologica lly inert and poorly immunogenic (49). 
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Purified capsule behaves immunologicall y like a hapten, and has been shown to interfere 
with phagocytosis and complement-mediated bacterio lysis ( l 0, 20, 25, 49). Serum resistance 
may be due to the capsule 's ability to evade complement fixation by C3b by either the 
alternate or the classical pathways (49). P. haemo(vtica STI and Haemophi/us i1?fluen=a type 
B are good examples of evading complement lysis ( I 0, 49) . However, specific immune 
serum is bactericidal through either of the complement pathways. In contrast, Actinobacil/us 
pleuropneumonia ST 5, a member of the HAP complex of organisms, is completely resistant 
to cell lysis in the presence of capsule-specific antibody and complement ( 49). Furthermore, 
an isogenic nonencapsulated mutant of A. pleuropneumonia ST 5 is susceptible to killing by 
complement alone thereby demonstrating that the capsule forms an important barrier between 
the pathogen and the host immune response (I 0, 49). Inzana hypothesized that encapsulation 
interferes with C3b fixation of the cellular membrane, thereby thwarting the early stages of 
the membrane attack complex (49). Although the cascade is activated, the capsule prevents 
the membrane attack complex from forming on the cellular membrane, thereby rendering the 
organism resi stant to complement. 
P. haemo(wica is resistant to phagocytosis in normal serum, and therefore is not c leared 
from the bloodstream or tissues of the host (I 0, 25, 75). Phagocytosis is thought to occur via 
a receptor mediated pathway whereby C3b or antibody opsonize the bacterium and receptors 
for C3b or the Fe region of the antibody a llow recognition of the opsonized complex by the 
macrophage (I 0, 51 , 75). Therefore, Pasteurel/ae which are able to evade opsonization tend 
to evade phagocytosis by alveolar macrophages and neutrophils. In addition to evading host 
immune responses, Morck has shown that P. haemo(vtica uses it's capsule to attach to 
alveolar epithelium (15, 64). Some reports have shown that fimbriae may act to support this 
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adhesion and therefore resist clearance by alveolar macrophages, however the mechani m by 
which thi occurs is not fully understood. Furthermore the ex istence of fimbriae is still under 
much debate thereby making elucidation of the mechanism of adhesion of Pasteurellae more 
difficult to study. 
Lipopolysaccharide 
Lipopolysaccharide produced by Pasteurella spp. is similar to LPS of other gram 
negative bacteria (49). It is composed of lipid A, a core oligosaccharide, and an antigenic 
polysaccharide chain referred to as 0 antigen ( 49). LPS has been studied extensively in 
Pasteurellae and other organisms. Its chemical composition has been determined and its role 
in pathogenic ity is briefly summarized below. 
P. haemo~vtica LPS is intimately associated with the capsule and capsular antigens. 
Hence. purificat ion of LPS has been difficult . evertheless, LPS ha been shown to be 
as ociated with immune protection of animals; the extent of the immune reaction depends on 
the animal species inoculated, LPS-type (either S or R types), route of inoculation and 
method of inoculation (96). Purified LPS has been determined to be antigenic and is found to 
be of the R-type. Pirosky isolated LPS-protein complexes and demonstrated that they were 
immunogenic and toxic (73). However, rabbit antiserum against the LPS antigen was shown 
to weak ly protect mice after challenge with LPS (22). Conversely, in some avian strains of 
Pasteurella anti-LPS antibody seems to be of importance in immunity (25, 78). Therefore, 
the efficacy of anti-LPS antibody against pasteurellosis is still somewhat unresolved. 
The effects of endotoxin occur through a two-fold mechanism (26, 49). During the first 
hour of exposure to LPS, a neutrophil independent event occurs whereby pulmonary 
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hypertens ion is observed w ithout increased vascular permeability. This response is primarily 
due to increased plasma cyclooxygenase-dependent arachidonic ac id metabolites, especially 
thromboxane A'J. and prostaglandin F2. In addition, cAMP levels in plasma elevate to a peak 
in I hour and cGMP elevate more slowly to a maximum at 12 hour. Emau et al. have 
suggested that the effects of endotoxin at the cellular level are mediated by the cyclic 
nuc leotides (29, 30). The second phase of LPS toxicity occurs wi thin an hour and is 
neutrophil dependent. Neutrophi ls infiltrate the lung, and cause an increase in vascular 
permeability due to secretion of mediators, e.g. leukotrienes, oxygen radicals, and proteolytic 
enzymes. Slocombe et al. (85) and Breider et al. ( 13) have found that neutrophils play an 
important role in the development of the severe lesions of bovine pneumonic pasteurellosis, 
especially fibrinous exudation and thrombosis. 
LPS de li vered by bronchoscopy to sheep lung led to a variety of clinica l and patho logical 
effects ( 16). A marked decline in circulating leukocytes was followed by mi ld leukocytosis. 
An inc rease in neutrophils was noted, and LPS evoked local inflammation, edema, 
hyperemia and hemorrhage in the lung (16, 85). The response to LPS in that experiment was 
comparable to acute pneumonia elic ited by live P. haemo(1•tica . 
There is evidence that LPS toxicity may be enhanced by complexing with lung surfactant 
( 15, 85). Brogden et al. found that after incubation of LPS with surfactant, surfactant vesicles 
formed and stabilized the LPS. This complex was significantly more dense than surfactant 
alone ( 15). They fo und that tox icity in mice with the complex was greatly enhanced over 
LPS alone. Goto and Rylander noted the same results using£. coli LPS ( 4). 
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Cytotoxins 
Many pathogenic bacteria make use of cytotox ins that target substrates found on the host 
cells to inactivate host cell de fenses. The c lassic example is that of the RTX toxin 
o.-hemolysin (HlyA) produced by the non-hemorrhagic strains of£. coli and the 
enterohemorrhagic toxin (EhxA) produced by hemorrhagic strains of £. coli (4, 7). The HlyA 
and EhxA toxins associate with the target cell and disrupt cellular membranes by fo rming 
pores and thereby lyse the ce ll (7). S imilarly, leukotox in, produced by P. haemozvtica 
disrupts cell membrane structures ultimately lysing the cell. 
C lassically, two exotoxins have been associated with P. haemozvtica, hemolysin, which 
gave rise to the P. haemo(1•tica species name, and leukotoxin. However, recently, Murphy et 
a l. constructed a leukotoxin mutant by a llelic exchange and demonstrated typical ~-hemo lytic 
activ ity on sheep and rabbit blood agar was abo lished. S imilar results were confirmed in our 
lab and therefore suggest that hemo lysin and leukotoxin are one in the same (65). 
Leukotoxin (LKT) has received much attention due to its ability to destroy cells invo lved 
with adherence and immunity. In the late 1970 and early 1980s studies of P. haemozvtica 
culture supem atants or washed cells demonstrated toxic ity for bovine al veo lar macrophages 
(8, 60). These studies yielded evidence that LKT was involved in the destruction o f 
macrophages and neutrophils, and Jent credence to the thesis that much of the pathological 
cellular damage of the host was due to destruction of host granulocytes. Hence, isolation, 
identification and eluc idation of the role of LKT on the pathogenesis of P. haemoz\'tica have 
been investigated extensively. 
Leukotoxin is produced by all known serotypes of P. haemoly tica (25) with the exception 
of fo ur untypable strains (4). LKT, a RTX toxin, shares a high degree o f homo logy to the 
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E.coli a-hemolysin at the nucleotide level (4). Researchers have postulated that LKT plays a 
role in virulence by causing cytolysis of alveolar macrophages and neutrophils. Furthermore, 
LKT induces platelet destruction and release of fibrinogen and vasoacti ve compounds as 
additive affects in the infected lung lesion (25). It has been suggested that LKT has a duel 
action dependent on concentration of the tox in in the microenvironrnent and the cells present 
(4, 86) . That is, ruminant leukocytes exposed to low leve ls of LKT have reduced phagocytic 
and oxygen radical generation capabilities. Conversely, high levels of LKT lyse leukocytes 
and platelets (25, 86). In an attempt to explain the activation-inhibition paradox, Steven and 
Czuprynski determined that cell death was in part mediated by apoptosis (86). They noted 
marked cytoplasmic membrane blebbing (zeiosis) and chromatin condensation and 
margination, the hallmarks of apoptosis. In another study, however, LKT effects on bovine 
neutrophils included ruptured membranes, numerous vesicles within the cytoplasm and 
pyknotic nuclei, all hallmarks of necrosis (4). These studies, however, are not universally 
accepted, though they do demonstrate the detrimental effects of LKT on bovine leukocytes 
and may, in part, explain the contrast between commensal or pathogenic P. haemolytica. 
Leukotoxin has shown specificity for ruminant leukocytes whereas nonruminant 
leukocytes and other cell types such as kidney cells, fibroblasts, and endothelium are 
resistant (25, 83). This specificity may define the different forms of pneumonia associated 
with P. haemolytica and P. multocida. In the former, a fibrinous pneumonia is most often 
described whereas the latter usually produces a purulent pneumonia (34). This striking 
difference may be attributed to the production of dermonecrotic toxin (DMT) by P. 
multocida that seems to have affinity for porcine osteoclasts (32). The DMT has little if any 
effect on ruminant leukocytes whereas LKT will lyse them (32) . It has been postulated that 
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the release of toxic intermediates and inflammatory mediators from lysed and activated 
leukocytes contributes to the cellu lar damage and inflammation in the lung resulting in a 
fibrinous pneumonia (25, 34). Analysis of the lung shows focal arrays of cellular damage 
where toxic intermediates have killed host tissue (34). 
Characterization of LKT at the molecular level has revealed that the toxin is a protein with 
a molecular mass of I 05 kDa. Purified leukotoxin has an isoelectric point between 4.1 and 
4.6 and retains activity at pH 4.5 through pH 9 (4). The gene coding for LKT, /kt, has been 
c loned and sequenced (23, 56, 57). More recently, studies have focused on the lkt operon and 
construction of !kt mutants to further investigate the role of LKT in disease ( 43). The /kt 
operon has the typical RTX family genetic arrangement. It is comprised of four genes 
designated lktC-lktA-lktB-lktD, where the lktC gene product, 19.9 k.Da, is required for 
activation of the proleukotoxin to the mature leukotoxin by posttranslational acylation of the 
LKT peptide (7, 3 1 ). The lktA gene encodes the structural toxin and lktB, 79.6 kDa, and lktD, 
54.7 kDa, genes are associated with exportation of the mature toxin to the extracellular 
environment (9). 
Previous studies have correlated high serum antibody responses to LKT with resistance to 
experimental challenge of cattle (37). Furthermore, recent studies by Lainson et al. confirmed 
that LKT was immunogenic when a fktA:lacZ fusion reacted with a strongly neutralizing 
monoclonal antibody localized to a 32 amino-acid region near the C-terminus of the 
leukotoxin A molecule (53). These studies provide the knowledge needed to construct LKT 
mutants targeting operon sequences other than the lktA gene sequences. Based on these 
studies, one can speculate that mutants designed to retain immunogenicity while abolishing 
toxicity may be of great advantage. 
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Secreted en zymes 
Prokaryotic organisms under harsh conditions have developed modalit ies of survival that 
involve the production of enzymes that can be secreted into the microenvironment to 
neutralize deleterious molecules present on the host cell surface (47, 87, 88, 90, 94). Some of 
these enzymes target cell surfaces and c leave acidic residues to make the microenvironment 
more habitable. Neuraminidase and g lycoprotease (generally referred to as sialidases) c leave 
N-linked and 0-linked sia loglycoconjugates, respectively, into free sialic acid residues (63). 
Pathogens such as Vibrio cholera (94), Bacteroides ji-agilis ( 47) , Salmo11e/la typhimurium 
L T2 (47), P. haemoly tica (87, 90), and P. multocida (88) contain sialidases. These organisms 
also contain genes that allow them to ingest and metabolize the released sialic acid re idues 
(47, 87, 88, 90, 94, 95). Other organisms such as£. coli don't contain sia lida e genes, but 
they may contain systems for uptake and degradation of scavenged free s ia lic acid residues 
(95). In this fashion host cell surface defenses are used to propagate the invading pathogen by 
neutralizing their protective capacity. Gottschalk demonstrated thi s phenomenon by 
removing the s ialic acid from salivary g lycoprote ins and noted the ir reduced protective affect 
against pathogens (42). In these cases the pathogen strips away the sialic acid and allows 
attachment and format ion of microcolonies (89). 
The first report of Pasteure!la spp. producing neuraminidase was by Scharmann et al. in 
1970 (80). In that report, 3 of 5 stra ins of P. haemo~vtica and l 02 of I 04 strains of P. 
multocida were shown to produce neuraminidase. In 198 1 Frank and Tabatabai examined P. 
haemoly tica and found that biotype A erotypes I, 5, 6, 7, 9, and 12 and no biotype T strains 
produced neuraminidase (35). However, a later report by Straus et al. demonstrated that all 
serotypes except serotype 11 of P. haemolytica biotype A produced neuraminidase (87). 
21 
These neuraminidases were characterized with neutralizing antibody from P. haemo(\"fica 
A I, by substrate specific ity. and by molecular weight and found they were imilar. 
The role neuraminidase may play in the vi rulence of P. haemo(wica in \fro i still unclear. 
Jn vivo production of anti-neuraminidase antibodies occurs during experimental infection 
with P. haemolytica suggesting that neuraminidase is induced during infection, and based on 
prev ious reports, one may hypothesize that neuraminidase may play a ro le in mucosa! 
colonization and survi val of the pathogen (82, 84. 89, 48). Presponse1m, a vaccine developed 
in the late 1980s by Shewen and colleagues, utilized the so luble antigens; leukotoxin, a 
serotype-speci fi c outer membrane protein, neuraminidase, and sialoglycoprotease harvested 
during logarithmic phase of P. haemo(vtica (82, 84) to protect cattle against P. haemo(vrica 
ST I. They demonstrated in both field and laboratory trials that Presponse1m was effective in 
preventing disease in cattle (54, 82, 84). 
Otulakowski was the first to describe the glycoprotease of P. haemo(vrica in the early 
1980s ( 4). He demonstrated the fo rmation of a protease specific for s ialoglycoproteins of 
human erythrocytes and cytotoxic for bovine pulmonary macrophages. In 1990 Abdul lah et 
a l. showed that g lycoprotease was found in culture supematants of P. haemo(vtica ST I, 2, 5, 
6, 7, 8, 9, and 12 by degradation of g lycophorin A ( l ). However, no activity was fo und in ST 
3, 4, I 0, and I I. In 1991 the same group reported they had c loned the P. haemo(vrica ST I 
glycoprotease gene and expressed it in E.coli (2). Furthermore, in 1992 they characterized the 
enzyme and reported it as a neutral metalloprotease that specifically cleaves 0-linked 
sia loglycoconjugates, in effect confirming the work of Otulakowski (3). Lee et al. 
demonstrated that in vivo production of glycoprotease results in antiglycoprotease antibody 
production in calves suggesting the presence of the enzyme during pathogenes is of P. 
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haemo(l'rica (54). The role of this enzyme seems to parallel that of neurarninida e, but 
relativel y little work has been done to conc lusively demonstrate this point (63) 
The role of secreted enzymes has not been clearly shown in the pathogenesis o f P. 
haemo(wica . However, work toward producing mutant P. haemo(vrica ST I devoid of 
neurarninidase or glycoprotease is underway and may provide the evidence needed to link 
these enzymes to virulence (9 1 ). 
Vaccination 
Vaccination has been an important strategy in controlling the incidence of pasteurellosis. 
Multiple types of vaccines have been used to vacc inate cattle and sheep against P. 
haemo(1•1ica inc luding subunit vaccines, bacterins, supernatant fractions, and live attenuated 
vacc ines strains (2, 5 , 18, 22, 24, 25, 34, 39, 40, 45, 49, 50). Commerc ial multicomponent 
vacc ines are c urrently available utiliz ing antigens from P. haemolytica biotypes T3, T4, TI 0, 
and T 15 that are invo lved in the septicemic fo rm of pasteurellosis (50). However, few 
effective vaccination protocols are currently available to protect sheep against pneumonic 
pa teurellosis, and those that are available show marg inal efficacy (34). Several cattle 
vacc ines are available which confer moderate protection, but these are ineffective in sheep 
due to serotype specificity and a lack of cross protection (34). 
As of 1989, inactivated bacterial preparations, bacterial extracts and some live 
preparations have been used as vaccines in cattle and sheep without much success (34, 39). 
For example, Rodger et al. used a parainfluen::a 3 (Pl3) virus attenuated li ve vaccine 
(originally licensed for use in cattle) to vaccinate sheep intranasally based on the premise that 
Pl3 is a predisposing factor to pasteurellosis in cattle (79). Ewes that seroconverted to PB 
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were either immune to the disease or showed reduced inc idence of pasteurellosis (79). 
However, this study also demonstrated that this vaccine protected sheep from pneumonic 
pasteurellosis temporarily, for one season. 
Vaccine fai lures have led to increased interest in the role of mucosa) immunity in 
protection. Early experiments by Wells in the late 1970s using sodium salicylate extracts of 
P. haemolyiica A I to immunize sheep followed by inocu lation with PI3 virus (to predispose 
the animals to di sease) showed that animals that were challenged 7 days after vaccination 
with P. haemo(vtica A 1 succumbed to infection (96). This led Wells to conclude that 
humoral immunity was not sufficient to provide protect ion. He speculated that cell-mediated 
immunity must play a key role in protection against pneumonic pasteurellosis (96). In a 
separate study, however, passive transfer of purified and nonpurified convalescent serum 
from e ither conventionally reared sheep that presented with pneumonia or experimentally-
infected sheep immunized with a P. haemo(vtica A2 vaccine to specific pathogen free lambs, 
protected 94- 100% of the animals (50). The authors concluded that humoral immunity was 
sufficient to prevent pasteurellosis. This apparent contradiction illustrates the complexity 
associated wi th assessing immunological resistance to pneumonic pasteurellosis. 
Vaccination studies continued, however, desp ite the lack of understanding of mucosa I 
immunity. For example, Chandrasekaran compared an oi l adj uvant vacc ine consisting of 
locally isolated P. haemo~vtica ST 7 and P. multocida serotypes A and D from infected sheep 
to the commerc ially available Carovax vaccine (Wellcome Laboratories) in imported cross-
bred lambs (22). A lthough the oi l adjuvant vaccine reduced lung lesions as compared to 
contro ls when P. haemolytica was used for challenge, lambs challenged with both P. 
haemolytica and P. multocida were not protected from pneumonic lesions. Carovax was also 
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found to be ineffective at reducing lesions in lamb infected with both Pasteurellae (22, 30). 
In another study, a sodium salicy late extract of P. haemo(\'fica ST2 grown in iron replete 
media to induce the express ion of iron regulated proteins was used to vaccinate specific 
pathogen free lambs (40). In this study some protection was conferred to SPF lambs after 
aerosol cha llenge with P. haemoly tica A2. Another example is the vaccine Presponse1m 
developed by Shewen and colleagues in the late 1980s. It is comprised of soluble antigens 
evolved from logarithmic growth phase P. haemolytica STI and both fie ld and laboratory 
trials have shown promise in protection against pneumonic pasteurellosis in cattl e (54, 82, 
84). 
These vacc ines are all examples of either bacterins or supernatants used to elicit protective 
antibodies in the immunized animals. A number of li ve vaccines of P. haemolvtica have been 
used and none required transformation of the bacterium. However, current technologies now 
allow geneti c manipulation of P. haemo(vtica to be possible, and for the first time y ield s ite 
directed mutants for the purpose of vaccine development. However, work to refine and 
evolve bacterins, extracts with new adj uvants, etc. is ongoing, and as yet, efficacy in the field 
has not met with expectations of the user. There fo re rationally attenuated li ve vaccines have 
become more desirable. 
The use of rationally attenuated live vaccines in the control of pasteurellos is in cattl e and 
sheep is a relatively new field (91 ). Construction of live attenuated vaccines has become 
feasible since the genes involved in restriction-modification of exogenous DNA have been 
characterized ( 14 ). Construction of attenuated mutant strai ns may prove to be better vaccine 
candidates then their predecessors. Previous studies by Collins et al. noted that live vaccines 
appear to protect better than bacterins because they e licit a stronger cell-mediated immune 
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response (24). In addition, humoral immunity is enhanced in li ve preparations due to the 
induction of genes during in vivo growth (92). Therefore, with the stronger immunity elic ited 
by live vaccines, attenuated live P. haemo(l1tica may prove to be of great importance in 
controlling pneumonic pasteurellosis (24, 92). 
With these arguments in mind, our aim in this study was to develop a rational ly attenuated 
strain of P. haemo~vtica ST 2 for use as a live vaccine candidate. Previous studies have 
demonstrated that the attenuation of vi rulent organisms through mutation of the aroA gene 
has produced effective auxotrophic mutant strains (6, 12, 21 , 27, 44-46, 70, 93, I 01 ). 
Use of auxotrophic aroA mutants as attenuated live vaccines 
The aromatic amino acids phenylalanine, tyrosine and tryptophan are essential fo r growth 
of all known life forms. Elucidation of the biosynthetic pathway(s) of each of the aromatic 
amino acids has been reported (38, 101 ). Moreover, the pathways consist of an elegantly 
arranged cascade of reactions containing molecules that converge into a branch point reaction 
whereby all of the aromatic amino ac ids are derived. Elimination of the precursor reactions, 
therefore, truncates the pathway and the organism cannot synthesize these amino acids. 
Figure 2 shows the pathway(s) involved and the common intermediates required for the 
synthesis of the aromatic amino acids (101). Briefly, glucose is catabolized to phosphoenol 
pyruvate and erythrose 4-phosphate through the glycolysis pathway (38). These two 
molecules then proceed through a common "shikimate" pathway to yield chorismate (38). 
Chorismate is know as a "common branchpoint" molecule from which all three aromatic 
amino acids are synthesized as well as fo late, vitamin K, ubiquinone, and 2,3-
dihydroxybenzoate (38). The enzyme 5-enolpyruvylshikimate 3-phosphate synthase (aroA) 
Figure 2. Biosynthetic pathway of the amino acids tyrosine, phenylalanine, and tryptophan. 
(Biochemistry third edition, Zubay, 1993) The enzyme 5-enolpyruvylshikimate 3-phosphate 
synthatse (aroA) catalizes the reaction that converts sh ikimate 3-phosphate to 5-
enolpyruvylshikimate 3-phosphate. Mutation of the aroA gene blocks this pathway thereby 
starving the organism of these essential amino ac ids. 
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is responsible for catalyzing the reaction that converts shikimate 3-phosphate to 5-
enolpyruvylshikimate 3-phosphate. The product is a precursor to the common branchpoint 
molecule chorismate from which all three aromatic amino acids are derived. Mutation in the 
aroA gene eliminates the precursors necessary for biosynthesis of all three amino acids 
thereby creating an auxotrophic mutant phenotype that relies on exogenous aromatic amino 
acids for proper protein synthesis. Mutants of this nature should lack the ability to survive in 
vivo for Jong periods of time, therefore making them good vaccine candidates. Organisms 
mutated in the aroA gene locus have been well characterized in the literature for use as 
rationally attenuated live vaccines (6, 12, 2 1, 27, 44-46, 70, 93, I 01 ). 
In 1950, Bacon et al. were the first to demonstrate attenuation of Salmonella typhi after 
mutation in the aromatic amino acid biosynthetic pathway (6). Subsequent efforts with 
pathogens such as Salmonella typhimurium (46), S. enleritidis (27), Shigellajlexneri (93), 
Yersinia enterocolitica ( 12), Y. pestis (70), Neisseria gonorrhea (21 ), Pasteurella multocida 
(44), and P. haemolytica ST I (45, 92) have produced add itional aroA mutants as vaccines 
candidates. 
Mutants of the aromatic amino acid fami ly have shown some promise in Pasteurella spp. 
Homphampa et al. observed that a live aroA P. multocida mutant completely protected mice 
that were immunized intraperitoneally twice and subsequently challenged with the parental 
strain ( 44 ). Two years later the same researchers demonstrated the efficacy of an aroA 
mutant of P. haemolytica ST! in mice that were immunized intraperitoneally twice and 
subsequently challenged with a lethal dose of the parental strain (45). Moreover, Adlar 
recently demonstrated attenuation after observing a 6-log increase in infectious dose 50 in 
mice exposed to aroA P. multocida ST I and 3 mutants (5). Furthermore, virulence was 
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restored by complementation of the mutant with a copy of wild type aroA in trans. These 
studies provide evidence that supports the contention that inactivation of the aroA gene 
effectively attenuates Pasteurella spp. and may be a useful means to produce an effecti ve 
li ve vacc ine in sheep against P. haemo~1·tica A2. 
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MATERJALS AND METHODS 
Bacterial strains and growth 
Luria broth (LB) and 2xYT were prepared as described (59). Columbia broth and 
Columbia agar were prepared according to the manufacturer's d irections (Difeo, Detroi t, 
Mich.). Wessman defined media (97) lacks the amino acid tryptophan, therefore, organ isms 
harboring a mutation in the aromatic amino acid biosynthet ic pathway cannot grow on this 
media. A protocol is supplied in Appendix A. Ampicillin ( I 0 µg per ml) and kanamycin (50 
µg per ml) were used for selection w ith P. haemo~vtica NADC-D 153 ST I and NADC-D 171 
ST2. For£. coli strains, ampic illin (I 00 µg per ml), kanamycin (50 µg per ml), and 
tetracycline (35 µg per ml ) were used fo r appropriate selection. All strai ns were grown at 
37°C unless otherwise stated . A summary of the bacterial strains and plasmids appear in 
Table 3. 
C loning of the P. haem olytica serotype 2 aroA gene 
Polymerase chain reaction (PCR) primers ( integrated DNA Techno logies [IDT] , 
Corra lv ille, Ia.) were designed based on the ST! aroA DNA sequence (92) and used to 
amplify the ST 2 aroA from P. haemo~1 ·1ica NADC-DI 7 1. A logarithmic phase P. 
haemo~1 ·tica culture grown in Columbia broth at 37°C fo r 3 h w ith shaking were used as the 
template ource. The fo rward primer, 5' -TATGAGGCATTACTGCGTGAAGG-3', 
des ignated D 17 1 # l hybridized to nuc leotides I through 23 of the minus strand, the reverse 
primer, 5'-AGCGGTTGGGCTTAGTCTGCCAC-3', designated 01 7 1#2 hybridized to the 
plus strand at nucleotides 1534 through 1556. PCR was carried out on a therrnocycler 
(Perkin- Elmer 9600 Therrnocycler, Perkin-Elmer Inc. , Branchburg, N.J.) according to the 
Table 3. Bacterial strains and plasmids used in this study 
Strain or plasmid 
Strains 
E.coli 
AB2829 
DHlOB 
PhaIMtase 
P. haemolytica 
NADC-0153 
NADC-0171 
Plasmids 
pSK 
pD70 
pD80 
pPharoA 1 
pPharoA 2 
pPharoA 3 
pPharoA 3.1 
pPCRllaroA 
pPhAmpr 
Characteristics 
K-12 strain harboring a mutation in the aroA gene 
Standard cloning strain used in this study 
Recombinant DH I OB harboring them Pha I methyltransferase gene 
Serotype 1, plasmidless 
Serotype 2, plasmidless 
Cloning vector (Ampr) 
3.5 kb plasmid encoding Kanr 
4.2 kb plasmid encoding Ampr 
3.2 kb Hind111 clone of P. haemo/ytica aroA (pSK) 
2.2kb Hindlll-Cla I digested pPharoA l aroA fragment (pSK) 
Same fragment as pPharoA 2 cloned on pBC SK 
200 bp Nde 1-BstEI I deletion of aroA from pPharoA 3 
Serotype 2 aroA PCR product cloned onto pPCRll TA cloning vector 
2.2 kb Sau3AI fragment of pD80 cloned onto pBC SK 
Source or reference 
92 
Gibco-BRL 
14,92 
NADC3 (R. Briggs) 
NADC (R. Briggs) 
Stratagene 
NADC (R. Briggs) 
NADC (R.Briggs) 
92 
92 
92 
This study 
This study 
92 
pPharoA ·ampr pPharoA 3.1 with Ampr gene from pPhAmpr cloned into the Nde 1-Bst Ell site This study 
pBB I 92C Broadhost range temperature sensitive This study 
pBB I 92C6aroA ·ampr Bss HI 6aroA ·ampr cassette from pPharoA ·ampr cloned on pBB 192C This study 
a NADC, National Animal Disease Center, Ames, Iowa. 
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manufacturer's directions in a total volume of 50 µI with 1 µI of cel ls us ing the ampliTaq 
Gold system (Perkin-Elmer). The cyc le program was as follows: I 0 seconds at 95°C; I 
minute at 95°C; 2 minutes at 55°C; 3 minutes at 72°C; 7 minutes at 72°C; hold at 4°C. Steps 
2-4 were cycled 30 times. 
The ST 2 aroA PCR product was ligated into the pPCRII TA cloning vector ( lnvitrogen 
Inc, San Diego, Calif.) using T4 DNA ligase (Bethesda Research Laboratories [BRL], 
Gaithersburg, Md.). The ligation mix was diluted I : I 0 in steri le dH 20 and used to transform 
electrocompetent E. coli DH- I OB (BRL) cells (Gene Pulser, Bio-Rad Laboratories, 
Richmond, Calif.). Cells were recovered for 1 h at 3 7°C in I ml of SOC broth (2% Bacto-
Tryptone, 0.5% Bacto Yeast Extract, 8 mM NaCl, 2.5 mM KCI, I 0 mM MgC)i, and 20 mM 
glucose) and then spread onto B-Agar plates ( 1% Bacto-Tryptone, 0.8% NaCl, 2% Difeo 
agar, 10 µg per ml thiamine) containing 0.002% 5-bromo-4-chloro-3-indo lyl-P-D-
galactopyranoside (X-Gal), 100 µM isopropyl-P-D-thiogalactopyranoside (IPTG) and 
ampicillin and grown overnight at 37°C. 
Seven white co lonies were picked and each was grown in 2 ml of 2x YT (59) broth 
containing ampicillin. Double stranded plasmid DNA was prepared by a standard alkaline 
lysis method (59). Plasmid DNA was digested with EcoRI (Bethesda Research Laboratories), 
and electrophoresed on a I% agarose gel (data not shown). One isolate containing a 1.5 kb 
insert was chosen for further study was designated pPCRIIaroA. 
Nucleotide sequencing of the P. haemolytica serotype 2 aroA gene 
Fourteen primers were designed and synthesized (IDT) util izing the ST 1 aroA published 
sequence for both the plus and minus strands (92). Cesium chloride purified (59) double 
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stranded pPCRIIaroA plasmid was used as template for sequencing reactions (Iowa State 
University Nucleic Acid Facility, Ames, IA.), and the nucleotide sequence (Automated 
Sequencer ABI Prism Model 377 Version 3.0 ABI200 Version 2.1.1.) of aroA was 
determined (MacDnasis Pro, Hitachi Software Ltd., San Bruno, Calif. and MacVector, 
Kodak Co., New Haven, Conn.) for both strands. 
Plasmid and P. haemolytica serotype 2 aroA mutant constructions 
To construct an aroA mutant of P. haemolytica ST2, we used an existing replacement 
plasmid containing the P. haemolytica ST 1 aroA as described by Tatum et al. (92). Briefly, 
the ST I aroA was c loned in the fo llowing way. A 1.3 kb PCR amplified£. coli aroA 
fragment was used to probe HindIII digested P. haemozvtica STl genomic DNA revealing a 
3.2 kb band. HindIIl digested P. haemozvtica ST 1 genomic DNA was then fractionated by 
agarose gel electrophoresis, and the 3.0 kb-3.4 kb fragments were isolated and c loned into 
HindIII digested alkaline phosphatase-treated pBlueskript SK cloning vector (Stratagene, La 
Jolla, Calif.) . The resulting plasmid was designated pPharoA 1. Functional aroA was 
confirmed by complementation of an aroA- strain of£. coli K-1 2, AB2829. Restriction 
enzyme analysis of pPharoA I revealed that an insert of 3.2 kb had been cloned. Another 
plasmid, pPharoA2, was constructed by excision of an internal 2.2 kb Cla l-HindIII aroA 
fragment from pPharoA I and cloned into the Accl-Hindlll site of pBluescript SK. To permit 
engineering of a rep lacement plasmid, the 2.2 kb Clal-HindIIJ aroA fragment was ligated 
into the Accl-HindIII site of pBC SK (Stratagene). This plasmid was designated pPharoA3 . 
In order to construct a vector for allelic exchange, the aroA gene in pPharoA3 was 
di srupted by inserting a gel-purified ampicillin resistance cassette from the plasmid pPhampR 
(92) into a unique Ndel site of aroA. The resulting plasmid, pPharoA-ampr was amplified in 
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£. coli DH I OB Pha lMtase harboring the mPhal methylase gene to protect the DNA against 
Phal cleavage (14). P. haemolytica ST1-NADC-Dl 53 and ST2-NADC-Dl 7 1 were prepared 
fo r electroporation by the fo llowing protoco l. A 25 ml Columbia broth culture was incubated 
for 3 h at 37°C, the cells were centri fuged at 5,000 x g for 15 min, washed twice in 25 ml of 
272 mM sucrose at 0°C and resuspended in 272 mM sucrose to an equal vo lume of pelleted 
cells. One to five micrograms of DNA were introduced into 100 µl of competent P. 
haemo~vtica by electroporation (Gene Pulser, Bio-Rad) using 0.1 cm cuvettes (Bio-Rad) at 
15 KV /cm, 800 n and 25 µF. Time constants ranged from 9.0 to I 0.5 ms. Additional controls 
consisted of an endogenous P. haemo~l'lica plasmid from the NADC-D80 strain, pD80, 
bearing an ampicillin resistance cassette as the positive control, and a no DNA contro l. Cells 
were recovered in I ml of Columbia broth on ice for I 0 min and then transferred to 37°C fo r 
3 h with shaking. After 3 h, 10 Columbia agar plates containing ampicillin were spread with 
I 00 µI of transformed cells and incubated overnight at 37°C. The positive and negative 
contro ls were plated on Columbia agar containing ampicillin . Since no ampicillin resistant 
P. haemo~\l/ica ST2 were recovered after several efforts with pPharoA.ampr, it wa desirable 
to con truct and utilize a non-suicidal replacement plasmid. 
A deletion plasmid was constructed using the aroA gene from pPharoA3 and a novel 
plasmid, pBB I 92C. Plasmid pBB l 92C contains a temperature sensitive origin of repl ication 
cloned from an endogenous plasmid of P. haemo~vtica STl- ADC-D70, pD70, a kanamycin 
(kan) resistance cassette from the transposon Tn903 (ClonTech, Palo Alto, Calif), and the 
Co/El origin of replication for amplification in£. coli (unpublished data). A 200 bp deletion 
was created in the aroA gene of pPharoA3 by double digestion with NdeI and BstEil 
restriction endonucleases. The resultant ends were filled in using deoxynucleoside 
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triphosphates and the Kienow fragment of E. coli polymerase I. A 2.2 kb ~- lactamase gene 
was iso lated from plasmid pPhAmpr (92) by double digestion using the restriction 
endonuc leases HindIII and Xba i. The resultant ends were fi lled in as described above and the 
fragments was separated on a I% agarose gel and purified using a spin column (Supelco 5-
5600A GenElute Agarose Spin Column, Supelco Inc, Bellefonte, Pa.). The purified ~­
lactamase gene was mixed w ith the pPharoA3 vector and ligated wi th T4 DNA ligase. The 
resulting plasmid was des ignated pPharoA3. I . 
The ~aroA -ainpr fragment was exc ised from pPharoA3. I by digestion with BssHI and 
cloned into the Eco RI s ite of pBB l 92C after fi lling the ends to make each fragment blunt. 
The resultant replacement p lasmid, pBB l 92C~aroA-ampr, was methy lated by passage 
through £. coli P/ialMtase as described above. Approximately I µg of methylated 
pBB I 92~aroA -ampr was used to transform P. haemo~\'fica STl -NADC-0 153 and P. 
haemo~l'lica ST2-N ADC-D 17 1 as described above. Electroporated cells were transferred to I 
ml of cold Columbia broth and incubated at 4°C for I 0 min . The cell s were then recovered at 
the permissive temperature of 30°C fo r l h. After recovery, the cells were spread onto 
Columbia agar plates contain ing kanamycin and incubated 24 h at 30°C. 
Six kanamyc in resistant colonies were grown in 5 ml Columbia broth containing 
kanamyc in overnight at 30°C with shaking. To ensure that the P. haemo(vtica isolates 
contained the replacement plasmid and to determine that the plasmid did not rearrange, 
double stranded plasmid DN A was extracted by a standard alkaline lysis method (59), 
digested with Eco RI restriction endonuclease and separated on a I% agarose gel. One iso late 
containing plasmid DNA consistent with pBB l 92C~aroA -ampr was chosen fo r fu rther work. 
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In order to select for recombinant P. haemo(1•tica, cel ls containing pBB I 92~aroA -ampr 
were incubated at the nonpermissive temperature of 40°C on Columbia agar containing 
ampicillin. Resultant co lonies were passed to 2 ml of Columbia broth contai ning ampicillin 
and incubated overn ight at 40°C to confirm ampicillin resistance. The cultures were struck 
onto Columbia agar plates without selection and grown overnight at 30°C to ensure the 
single .crossover mutants were cured of plasmid. Individual colonies then were scored for 
ampicillin and kanamycin resistance and tryptophan auxotrophy by inoculation into 96 well 
microtiter plates containing Columbia broth with ampicillin, Columbia broth with 
kanamyc in, and Wessman defined media lacking the amino acid tryptophan and grown at 
37°C (97). 
Several iso lates were found to be ampicillin and kanamycin resistant and tryptophan 
negative. One such ST 2 iso late des ignated E 11 , was chosen for further study. To generate 
the desired aroA mutant via excision of the replacement plasmid from the chromosome, El 1 
was passed at 40°C in 2 ml Columbia broth with ampicillin selection for 5 h. Resultant 
growth was inoculated into 200 ml of Columbia broth without se lection and incubated 
overn ight at 30°C. After passage the culture was struck for iso lation onto Columbia agar 
without antibiotic and incubated overnight at 40°C. Resultant colonies were patched onto 
Columbia agar containing ampicillin and replica-patched onto Columbia agar containing 
kanamycin and were grown at 37°C overnight. Colonies which were both ampicillin resistant 
and kanamycin sensitive were passed in 2 ml Columbia broth containing ampicillin and 
incubated at 37°C overnight to confirm antibiotic resistance. Four co lonies confirmed the 
appropriate antibiotic phenotype were inoculated into 2 ml of Wessman broth. All failed to 
grow in the defined media. 
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Southern blots were perfo rmed on the putative aroA mutants to determine if double 
cro sover mutant were generated. Chromosomal DNAs were obtai ned from a ll 4 putative 
double crossover mutants in the fo llowing way. Cell were grown overnight in 25 ml 
Columbia broth containing ampici ll in at 37°C. The cells were pell eted by centrifugation fo r 
15 min at 5,000 x g, resuspended in lysis buffer (1 % sodium dodecyl sulfate (SDS), 15 mM 
EDTA, 60 mM Tris-HCI pH 7.5, 50 mM NaCl), and incubated for 30 min at room 
temperature. The resultant DNA was extracted 3 times w ith an equal volume of chloroform 
and precipitated w ith 2 vo lumes 95% ethanol. The DNA was pe lleted by centri fugation fo r 
15 min at I 0,000 x g and washed in co ld 70% ethanol. The DNAs were resuspended in 2 ml 
TE buffer, and samples were quantitated spectrophotometrically as described by Maniatis 
(59). 
One microgram of genomic D A from putative mutant and wild type ST2-NADC-D 17 1 
were d igested with HindII I. Plasmid pBB I 92C~aroA ·ampr was d igested with Sspl. The 
DNAs were fractionated on 0.8% agarose gels. The ge ls were subsequentl y denatured in 1.0 
M NaCl and 0.5 M NaOH for 30 min, neutralized w ith 3.0 M NaCl and 1.5 M NaOH fo r 30 
min, and D NAs were transferred to a ny lon membrane (Hybond-N; Amersham Corp., 
Arlington H eights, Ill .) by capillaryphoresis according to the procedure of Man iatis (59). 
Filters were baked for I h at 80°C fo llowed by incubation with prehybridization so lution 
(5X SSC ( IX SSC is 0. J 5 M NaCl and 0.0 15 M sodium citrate), 5X Denhardt ' s so lution (59), 
0. 1 % SOS, I 0 µg per ml sonicated salmon sperm DNA, and 50% formamide] at 42°C fo r 30 
min. The prehybridization so lution was removed and replaced w ith hybridization solution 
(prehybridization so lution w ithout Denhardt ' s solution) containing 107 cpm o f 32P-labeled 
probe. Probes were prepared from a gel purified 2.2 kb fragment containing the ST I aroA 
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gene or linearized plasmid pBB l 92C using a random hexanucleotide radiolabeling kit 
(Boehringer Manneheim) and [32a -P]dCTP. Filters were hybridized at 42°C for 18 h and 
washed twice with wash so lution ( 1 X SSC and 0.1 % SOS) at 42°C fo r 15 min and once at 
65°C for 15 min. Membranes were exposed to X-AR (Eastman Kodak Co., Rochester, .Y.) 
film at -70°C for 2 h. One isolate designated, F9.80, showed genetic characteristi cs 
consistent with allelic exchange of the host chromosomal aroA gene and the tiaroA-ampr 
replacement cassette as demonstrated when probed with gel-purified radio labeled aroA. 
Moreover, F9.80 genomic DNA was shown to be devoid of vector sequences when probed 
with radio labeled pBB l 92C vector. 
To conclusively demonstrate that F9.80 was an aroA deletion mutant, Southern blot 
analysis was repeated. One microgram of Hind III digested genomic DNA of parental P. 
haemoZvtica NADC-D 171, P. haemoZvtica NADC-D 171 tiaroA-ampr mutant F9.80, and 15 
ng of Soil digested pBB 192CtiaroA-ampr linearized plasmid were fractionated on an agarose 
gel as described above. Southern blots were performed as described above and the filters 
were probed with P. haemofytica NADC-060 (STI) aroA ; linearized pBB192C plasmid, and 
the 200 bp NdeI-BstEIJ fragment from STl aroA respectively. Furthermore, tryptophan 
auxotrophy confirmed that F9.80 was a mutant in the aromatic amino acid biosynthetic 
pathway. Inoculation of the mutant into Columbia broth containing ampicillin, Wessman 
defined media Jacking tryptophan, and Wessman defined media containing tryptophan (0.5 
µg per ml ) and monitoring growth was performed to demonstrate auxotrophy. 
In addition to the genomic endonuclease restriction pattern observed above, final 
confirmation that F9.80 was P. haemolytica serotype 2 was performed when F9.80 was 
struck onto blood agar plates containing 5% sheep erythrocytes and incubated overnight at 
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37°C for observation of f3-hemolysis (34). Jn addition, rapid plate agglutination us ing ST I 
and ST 2 specific antiserum was performed by mixing a sample of ce lls harvested from 5 % 
sheep blood agar plates with the specific antisera and observing aggl utination (36) to confirm 
the authenticity o f the P. haemolytica aroA mutant serotype. 
Nucleotide sequence accession number 
The P. haemolytica ST2 aroA sequence reported here was deposited in Genbank under the 
access ion number U89948 and a copy is supplied in Appendix B. 
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RESULT AND DISCUS ION 
C loning of the P. ltaem olytica serotype 2 aroA gene 
Two spec ific primers corresponding to P. haemo~1·tica STI aroA gene sequences were 
used to synthes ize by PCR a 1.5 kb aroA product using P. haemolytica ST 2 genomic DNA 
as template. Previous studie indicate that the nucleotide sequence of aroA , an essential 
housekeeping gene in bacteri a, is highly conserved across many genera of prokaryotes (92, 
I 0 I). For instance, the aroA gene of P. haemo~vtica ST I shows 75, 70, 69, and 68% identity 
with the aroA gene sequences of P. multocida, Klebsiella pneumonia, Y. enterocolitica, and 
E. coli, respective ly (92). Therefore, it appeared likely that the P. haemo~vtica ST2 aroA 
nucleotide sequence would have a high degree of similarity to the ST I aroA nucleotide 
sequence. As expected, the primers ampli fied a 1.5 kb product from ST2 equal in size to the 
aroA from serotype I (data not shown). The PCR product was c loned into PCRII TA to 
generate plasmid pPCRI1aroA (Table 3) and the DNA sequence of the insert was determined. 
Nucleotide sequencing of the P. haem olytica serotype 2 aroA gene 
The P. haemo~vtica ST2 aroA sequence was obtained using fourteen different primers 
designed from P. haemo/ytica ST! aroA (92). The complete nucleotide sequence of the ST2 
aroA and the deduced amino ac id sequence are shown in Figure 3. An open reading frame of 
1,296 nucleotides encoded a 432 amino ac id res idue polypeptide. Serotype 2 aroA has a 
deduced molecular weight of 4 7 ,070 daltons, a %G+C content of 42% and an isoelectric 
point of 4.88. The gene had 99. 1 % identity to serotype 1 aroA suggesting a close relationship 
between these serotypes o f P. haemo/ytica. An erratum was detected in the original ST 1 
aroA sequence, discrepancies between ST I and ST2 aroA were confirmed by analysis of the 
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GTGATTGTTCGCTCGATAGCAGGTTATGGAATGCCGAATCATTTACGCATTAGTATCGGTTTACCGCAAGAAAACGAGAG 80 
M 
ATTTTTTACTGCCTTATTGAAAGTGTTAGCTTAACAAGCGGTTACCTTTTATGAAAATTTTACAAATTTAAAGAGAAAAA 160 
E K L T L T P I S R V E G E I N L P G S K S L S N R> 
TGGAAAAACTAACTTTAACCCCGATTTCCCGAGTAGAAGGCGAGATCAATTTACCTGGTTCTAAAAGCCTGTCTAACCGA 240 
A L L L A A L A T G T T Q V T N L L D S D D I R H M L> 
GCCTTATTATTAGCCGCCTTAGCCACCGGTACGACTCAAGTGACCAATTTATTAGATAGTGATGATATTCGACATATGCT 320 
N A L K A L G V K Y E L S D D K T V C V V E G I G G A> 
CAATGCCTTAAAAGCGTTAGGCGTGAAATATGAGCTATCGGACGATAAAACCGTCTGTGTAGTTGAAGGGATTGGTGGAG 400 
F K V Q N G L S L F L G N A G T A M R P L A A A L C> 
CTTTTAAGGTTCAAAACGGCTTATCACTGTTTCTCGGCAATGCAGGCACGGCAATGCGACCACTTGCAGCAGCATTGTGT 480 
L K G A E T A Q I I L T G E P R M K E R P I K H L V D> 
TTAAAAGGGGCGGAAACAGCTCAAATCATTCTTACCGGTGAGCCAAGAATGAAAGAACGCCCGATTAAACATTTAGTCGA 560 
A L R Q V G A E V Q Y L E N E G Y P P L A I S N S G L> 
TGCTTTACGCCAAGTAGGGGCAGAGGTACAGTATTTAGAAAATGAAGGCTATCCGCCGTTAGCAATTAGCAATAGCGGTT 640 
Q G G K V Q I D G S I S S Q F L T A L L M S A P L A> 
TGCAAGGTGGAAAAGTGCAAATTGACGGCTCGATTTCCAGCCAATTTCTAACCGCATTGCTGATGTCTGCCCCATTAGCG 720 
E S D M E I E I I G D L V S K P Y I D I T L S M M N D> 
GAAAGCGATATGGAAATTGAGATTATCGGTGATCTGGTATCAAAACCTTATATTGATATTACCCTTTCGATGATGAACGA 800 
F G I T V E N R D Y K T F L V K G K Q G Y V A P Q G N> 
TTTTGGTATTACGGTTGAAAATCGAGATTACAAAACCTTTTTAGTTAAAGGTAAACAAGGCTATGTTGCTCCACAAGGTA 880 
Y L V E G D A S S A S Y F L A S G A I K G K V K V T> 
ATTATTTGGTGGAGGGAGATGCCTCTTCTGCCTCTTATTTCTTAGCCTCCGGTGCGATTAAAGGCAAGGTAAAAGTAACG 960 
G I G K K S I Q G D R L F A D V L E K M G A K I T W G> 
GGCATTGGTAAAAAATCGATCCAAGGCGACCGCTTGTTTGCCGATGTGTTGGAAAAAATGGGGGCAAAAATCACTTGGGG 1040 
E D F I Q A E Q S P L K G V D M D M N H I P D A A M T> 
AGAGGATTTTATTCAAGCCGAGCAATCCCCGCTAAAAGGCGTAGATATGGATATGAATCATATTCCTGATGCGGCAATGA 1120 
I A T T A L F A E G E T V I R N I Y N W R V K E T D> 
CGATTGCAACAACCGCTTTATTTGCCGAAGGAGAAACAGTTATCCGCAATATTTATAACTGGCGGGTAAAAGAAACCGAC 1200 
R L T A M A T E L R K V G A E V E E G E D F I R I Q P> 
CGCTTGACAGCAATGGCAACCGAATTGCGTAAAGTCGGGGCAGAGGTAGAAGAAGGGGAAGATTTTATTCGGATTCAACC 1280 
L A L E N F Q H A E I E T Y N D H R M A M C F S L I A> 
GCTTGCGTTAGAAAACTTCCAGCACGCTGAAATTGAAACCTATAACGATCACCGTATGGCAATGTGTTTTTCATTAATTG 1360 
L S N T E V T I L D P N C T A K T F P T Y F R E L E> 
CGTTATCGAATACAGAAGTGACGATCTTAGATCCAAATTGTACCGCTAAAACGTTCCCGACTTACTTTAGGGAGTTGGAA 1440 
K L S V R 
AAATTATCGGTCAGATAAAAGTAAAAAAGGATTCAGAAAACTGAATCCTTTTTACGTTTTATTGTGGCAGACTAAGCCCA 1520 
Figure 3. Nucleotide sequence and deduced amino acid sequence of P. haemo~vtica NADC-
D 17 l ST2 aroA 
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original sequence autoradiographs of ST I aroA and the automated sequence results of ST2 
aroA. Corrections were made to the ST I aroA sequence where the autoradiograph of both the 
plus and minus strands agreed, and a homology comparison of the T2 aroA to ST! aroA 
was based on corrected sequence (Figure 4) . 
Previous studies by Tatum et al. demonstrated that P. haemo~1·tica ST I aroA, like P. 
multocida, was transcribed by its own promoter (44, 92). These observations were based on 
experiments demonstrating that the cloned aroA was capable of complementing a mutant 
strain of E. coli K-1 2 AB2829 independent of orientation in the plasmid (92). Furthermore, 
P. haemolytica ST! aroA was found to di ffer in genetic arrangement to other gram negative 
bacteria in which aroA and sere constitute an operon with aroA downstream of the sere 
promoter (92). The sere gene encodes a biosynthetic enzyme leading to the synthes is of the 
non-aromatic amino acid serine. Studies by Lim et al. utilizing a sere-aroA:: lacZ 
translational fusion, demonstrated that the E. coli aroA gene product is coordinately 
expressed by the sere promoter in a cAMP dependent manner (55). A comparison of the 
sequences upstream of the P. haemo~vtica ST I aroA gene on plasmid pPharoA2 
demonstrated no homology to sere genes thereby suggesting that aroA and sere do not 
constitute an operon in P. haemo~vtica. It remains unc lear as to why Pasteurella aroA 
possesses it own promoter. Other respiratory pathogens such as Haemophilus in.fluen::ae 
contain an aroA under the control of the upstream pwN promoter (6 1 ). In this example, the 
purN (glyc inamide ribonucleotide transformylase) stop codon overlaps the start codon of 
aroA suggesting that they may be translationally coupled. These studies indicate a regulation 
of aroA in response to environmental factors aside from synthesis of aromatic amino acids 
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STl a roA GTGATTGTTCGCTCGATAGCAGGTTATGGAATGCCGAATCATTTACGCATTAGTATCGGT 
****************************************** ** **** * *********** 
ST2 aroA GTGATTGTTCGCTCGATAGCAGGTTATGGAATGCCGAATCATTTACGCATTAGTATCGGT 
STl a roA TTACCGCAAGAAAACGAGAGATTTTTTACTGCCTTATTGAAAGTGTTAGCTTAACAAGCG 
***************** ********************** ********************* 
ST2 a roA TTACCGCAAGAAAACGAGAGATTTTTTACTGCCTTATTGAAAGTGTTAGCTTAACAAGCG 
STl aroA GTTACCTTTTATGAAAATTTTACAAATTTAAAGAGAAAAATGGAAAAACTAACTTTAACC 
************************************************************ 
ST2 aroA GTTACCTTTTATGAAAATTTTACAAATTTAAAGAGAAAAATGGAAAAACTAACTTTAACC 
STl aroA CCGATTTCCCGAGTAGAAGGCGAGATCAATTTACCTGGTTCTAAAAGCCTGTCTAACCGA 
*********************** ****************** ******************* 
ST2 aroA CCGATTTCCCGAGTAGAAGGCGAGATCAATTTACCTGGTTCTAAAAGCCTGTCTAACCGA 
STl aroA GCCTTATTATTAGCCGCCTTAGCCACCGGTACGACTCAAGTGACCAATTTATTAGATAGT 
************************************************************ 
ST2 aroA GCCTTATTATTAGCCGCCTTAGCCACCGGTACGACTCAAGTGACCAATTTATTAGATAGT 
STl aroA GATGATATTCGACATATGCTCAATGCCTTAAAAGCGTTAGGCGTGAAATATGAGCTATCG 
************************************************************ 
ST2 aroA GATGATATTCGACATATGCTCAATGCCTTAAAAGCGTTAGGCGTGAAATATGAGCTATCG 
STl a roA GACGATAAAACCGTCTGTGTAGTTGAAGGGATTGGTGGAGCTTTTAAGGTTCAAAACGGC 
************************************************************ 
ST2 aroA GACGATAAAACCGTCTGTGTAGTTGAAGGGATTGGTGGAGCTTTTAAGGTTCAAAACGGC 
STl a roA TTATCACTGTTTCTCGGCAATGCAGGCACGGCAATGCGACCACTTGCAGCAGCATTGTGT 
************************************************************ 
ST2 aroA TTATCACTGTTTCTCGGCAATGCAGGCACGGCAATGCGACCACTTGCAGCAGCATTGTGT 
STl aroA TTAAAAGGTGAGGAAAAATCCCAAATCATTCTTACCGGTGAACCAAGAATGAAAGAACGC 
******** l * l ***** l * l * l ******************** I ****************** 
ST2 a roA TTAAAAGGGGCGGAAACAGCTCAAATCATTCTTACCGGTGAGCCAAGAATGAAAGAACGC 
STl a roA CCGATTAAACACTTAGTCGATGCTTTACGCCAAGTAGGGGCAGAGGTACAGTATTTAGAA 
*********** !************************************************ 
ST2 aroA CCGATTAAACATTTAGTCGATGCTTTACGCCAAGTAGGGGCAGAGGTACAGTATTTAGAA 
STl a roA AATGAAGGCTATCCACCGTTGGCAATTAGCAATAGCGGTTTGCAGGGCGGAAAAGTGCAA 
************** l ***** l *********************** l ** I************ 
ST2 a roA AATGAAGGCTATCCGCCGTTAGCAATTAGCAATAGCGGTTTGCAAGGTGGAAAAGTGCAA 
Figure 4. Homology comparison between P. haemolytica NADC-060 ST I and P. 
haemoly tica NADC-D 171 ST2 aroA. The two genes display a 99. 1 % identical match. The 
A TG start codon and T AA stop codon are in bold and mismatches are denoted by vert ical 
lines. 
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STl aroA ATTGACGGCTCGATTTCCAGCCAATTTCTAACCGCATTGCTGATGTCTGCCCCATTAGCG 
** ********************************************************** 
ST2 aroA ATTGACGGCTCGATTTCCAGCCAATTTCTAACCGCATTGCTGATGTCTGCCCCATTAGCG 
STl aroA GAAGGCGATATGGAAATTGAGATTATCGGTGATCTGGTATCAAAACCTTATATTGATATT 
*** !******************************************************** 
ST2 aroA GAAAGCGATATGGAAATTGAGATTATCGGTGATCTGGTATCAAAACCTTATATTGATATT 
STl aroA ACCCTTTCGATGATGAACGATTTTGGTATTACGGTTGAAAATCGAGATTACAAAACCTTT 
******* * * ************************************** * ************ 
ST2 aroA ACCCTTTCGATGATGAACGATTTTGGTATTACGGTTGAAAATCGAGATTACAAAACCTTT 
STl aroA TTAGTTAAAGGTAAACAAGGCTATGTTGCTCCACAAGGTAATTATTTGGTGGAGGGAGAT 
************************************************************ 
ST2 aroA TTAGTTAAAGGTAAACAAGGCTATGTTGCTCCACAAGGTAATTATTTGGTGGAGGGAGAT 
STl aroA GCCTCTTCTGCCTCTTATTTCTTAGCCTCCGGTGCGATTAAAGGCAAGGTAAAAGTAACG 
************************************************************ 
ST2 aroA GCCTCTTCTGCCTCTTATTTCTTAGCCTCCGGTGCGATTAAAGGCAAGGTAAAAGTAACG 
STl aroA GGCATTGGTAAAAAATCGATCCAAGGCGACCGCTTGTTTGCCGATGTGTTGGAAAAAATG 
**** ******************************************************** 
ST2 aroA GGCATTGGTAAAAAATCGATCCAAGGCGACCGCTTGTTTGCCGATGTGTTGGAAAAAATG 
STl aroA GGGGCAAAAATCACTTGGGGAGAGGATTTTATTCAAGCCGAGCAATCCCCGCTAAAAGGC 
************************************************************ 
ST2 aroA GGGGCAAAAATCACTTGGGGAGAGGATTTTATTCAAGCCGAGCAATCCCCGCTAAAAGGC 
STl aroA GTAGATATGGATATGAATCATATTCCTGATGCGGCAATGACGATTGCAACAACCGCTTTA 
************************************************************ 
ST2 aroA GTAGATATGGATATGAATCATATTCCTGATGCGGCAATGACGATTGCAACAACCGCTTTA 
STl aroA TTTGCCGAAGGAGAAACAGTTATCCGCAATATTTATAACTGGCGGGTAAAAGAAACCGAC 
************************************************************ 
ST2 aroA TTTGCCGAAGGAGAAACAGTTATCCGCAATATTTATAACTGGCGGGTAAAAGAAACCGAC 
STl aroA CGCTTGACAGCAATGGCAACCGAATTGCGTAAAGTCGGGGCAGAGGTAGAAGAAGGGGAA 
**************************** ******************************** 
ST2 aroA CGCTTGACAGCAATGGCAACCGAATTGCGTAAAGTCGGGGCAGAGGTAGAAGAAGGGGAA 
STl aroA GATTTTATTCGGATTCAACCGCTTGCGTTAGAAAACTTCCAGCACGCTGAAATTGAAACC 
******** **************************************************** 
ST2 aroA GATTTTATTCGGATTCAACCGCTTGCGTTAGAAAACTTCCAGCACGCTGAAATTGAAACC 
STl aroA TATAACGATCACCGTATGGCAATGTGTTTTTCATTAATTGCGTTATCGAATACAGAAGTG 
************************************************************ 
ST2 aroA TATAACGATCACCGTATGGCAATGTGTTTTTCATTAATTGCGTTATCGAATACAGAAGTG 
Figure 4 (continued). 
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STl aroA ACGATCTTAGATCCAAATTGTACCGCTAAAACGTTCCCGACTTACTTTAGGGACTTGGAA 
********************************* ****** ************** ! ****** 
ST2 aroA ACGATCTTAGATCCAAATTGTACCGCTAAAACGTTCCCGACTTACTTTAGGGAGTTGGAA 
STl aroA AAATTATCGGTCAGATAAAAGTAAAAAAGGATTCAGAAAACTGAATCCTTTTTACGTTTT 
** ******* ************************************* ************** 
ST2 aroA AAATTATCGGTCAGATAAAAGTAAAAAAGGATTCAGAAAACTGAATCCTTTTTACGTTTT 
STl aroA ATTGTGGCAGACTAAGCCCAACCGCT 
** ******** **** *** ** **** *** 
ST2 aroA ATTGTGGCAGACTAAGCCCAACCGCT 
Figure 4 (continued). 
a lone. However, regulation of the P. haemo(vtica aroA gene remams to be examined. 
Consti tutive expression of aroA, however, may explain de novo synthesis of aromatic amino 
ac ids to support growth of P. haernolytica on Wessman defined media. 
A homology comparison between P. haerno(\'fica STI and ST2 aroA revealed 99.1 % 
overall sequence identity (Figure 4). Sequences upstream of the structural gene, however, 
were shown to be I 00% identical suggesting that ST2 aroA does not constitute an operon 
with serC. 
P. haemolytica mutant construction and characterization 
The purpose of this study was to construct an aroA mutant of P. haemo~\'tica ST2 and 
demonstrate its attenuation in vitro. Towards that end, several replacement plasmids were 
developed and introduced into P. haernolytica using new technology to protect the exogenous 
ONA from endogenous restriction barriers. Each plasmid developed was cons idered superior 
to the previous plasmid, which fai led to produce an aroA mutant. First, plasmid pPharoA3 
conta ining the P. haerno~vtica ST I aroA gene disrupted by an ampic illin resistance cassette 
was methylated by passing the plasmid through E. coli containing Pha!Mta eon a cosmid 
and subsequently using the plasm id to transform logarithmic phase P. haernolytica ST I and 
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ST2. Despite repeated attempts no transformants were obtained by using up to 5 µg of 
pPharoA3. Positi ve control p080 plasmids from£. coli Pha!Mtase transformed with a 
frequency of approximately 6 x 103 transformants per µg supercoi led DNA. These results 
indicated that Co/£1-based plasmids do not replicate in NADC-0 171. The relatively low 
effic iency of transformation with p080 implies that the larger pPharoA3 may have been 
introduced at levels too low for generating a mutant by allelic exchange (Figure 5). 
Previous studie by Tatum et al. employing a chimeric hybrid plasmid which contained 
both the P. haemo~vtica pD70 ori gin of replication (an endogenous plasmid of Pasteurelfa) 
and the ColE I origin of replication were successful in generating deletion mutations (92). 
This shuttle vector could replicate both in Pasteurelfa and in E. coli thereby circumventing 
the low transformation frequency observed with the introduction of suic ide plasmids into 
Pasteurelfa while allowing amplification of plasmid in E.coli. After its introduction into P. 
haemolytica the hybrid plasmid generated single crossover products. The authors found that 
the single crossover products were unstable, presumably due to the plasmid origin of 
rep lication destabiliz ing chromosomal replication (92). Since ant ibiotic selection was 
maintained, the unstable single crossover products would be eliminated if they reso lved to 
wild type during passage at 40°C due to loss of the excised hybrid plasmid. Only mutants 
arising by excision of the plasmid to produce a deletion mutant exhibited robust growth 
under antibiotic se lection. 
To permit more control over the plasmid system, a temperature sensitive shuttle vector 
was developed utilizing the ColEI origin of replication and a mutagenized P. haemo~vtica 
origin of replication derived from the streptomycin resistant plasmid p070. This plasmid, 
BssHI 
I 
x 
BstED Ndel 
I I 
I 
47 
pPbam43 
Digest with NdeI and BstEil and ligate Amp' 
fragment 
BssHI 
j pPbamA3 I 
l Excise &lroA-ampr cassette by digestion with BssHI, Bhmt, ligate into EcoRI site of pBBI 92C, methylate plasmid, electroporate in P. haemo~vtica serotype 2. 
x 
aroA I P haem chromosome 
AOJjf 
I Homologous recombination between replacerrent plasmid and chromosome to generate an aroA rrrutant. 
aroA I P haem ST2 mutant 
Figure 5. Construction of an aroA mutant of P. haemoly tica NADC-D 171 ST 2. The 
temperature conditional broad host range plasmid pBB l 92C carrying the t:..aroA-ampr 
cassette was employed to successfully develop an aroA mutant. 
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pBB I 92C, contained a kanarnyc in res istance cassette and was approx imately 3.5 kb in size . 
In the current study, a deletion was introduced into P. haemo~1 ·tica aroA and into the de letion 
site a 2.2 kb P. haemolytica arnpic ill in resistance cassette was inserted. The mutated aroA 
gene containing arnpr was cloned into pBB l 92C giv ing ri se to the plasmid pBB l 92CL'l.aroA-
ampr. This construct was able to overcome problems associated with the suicide vector 
described previous ly. The steps invo lved in constructing the replacement plasmid 
pBB I 92CL'l.aroA-ampr and generating a gene rep lacement mutant via allelic exchange are 
depicted in Figure 5. 
S ince pBB l 92C separates transformation and recombi nati on steps, it was antic ipated that 
transformation of P. haemolytica could be accompl ished. Plasmid pBB l 92CL'l.aroA-ampr was 
methylated by passage through E. coli Pha IMtase and used to transform P. haemo(vtica STl 
and ST2 by electroporation. Double stranded plasmid DNA was iso lated from six kanarnycin 
resistant co lonies and all plasmid DNAs analyzed by restriction enzyme digestion were 
shown to be pBB l 92CL'l.aroA-ampr. 
Since recombination is a rare event, amplification of a sing le transformant would result in 
the generation of large numbers of bacteria harboring the replacement plasmid and thus 
increase the like lihood that specific integration of the replacement plasmid into the host 
chromosome would occur. After growth at 30°C, the temperature was shifted to the 
nonpermiss ive temperature of 40°C or 42°C in arnpicillin se lection to prevent plasmid 
replication and promote integration of the plasmid into the host chromosome. It was fo und 
that passage of ADC-D 17 1 at >40°C resulted in unacceptably short duration of viability. 
Passage at 40°C resulted in acceptable viability and several co lonies were se lected for further 
study. These co lonies, in theory should contain recombination products with integrated 
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plasmids or double crossover mutants, however, our prev ious experience with P. haemolytica 
demonstrated that ampicillin selection was weak giving rise to several spontaneously 
res istant colonies on solid media which failed to grow in broth containing ampicillin. 
Therefore, co lonies from the plates grown at 40°C were passed in broth containing ampic illin 
and grown at 40°C to collect viable c lones. To induce a second recombination event that 
resulted in reso lution of the replacement plasmid and to cure the ce ll s of the remaining 
plasmids, the overnight culture was struck for isolation onto Columbia agar plates containing 
no antibiotic and grown at 30°C. Individual colonies were then scored for antibiotic 
resistance and auxotrophy. Construction of the replacement cassette y ielded a mutated aroA 
gene in which 200 bp of the N-terminal region of the aroA gene product was deleted. 
Therefore, a s ingle recombination event could produce one of two products based on the site 
of homologous recombination. If the integration of the plasmid resu lted from a 
recombination event occurring upstream of the deletion, an inactivated aroA gene would 
result. However, if the integration of the plasmid resulted fro m a recombination event 
occurring downstream of the deletion, a functional aroA gene would result. Therefore, by 
screening for P. haemolytica mutants unable to support growth in Wessman defined media, 
one would isolate s ingle crossover mutants occurring on the upstream arm of the replacement 
plasmid or products of double crossover events (Figure 6). As expected, several ampicillin 
and kanamycin resistant iso lates failed to grow in Wessman defined media. Southern blot 
analysis of Hincllll digested genomic DNAs from these isolates demonstrated the presence of 
integrated plasmid DNA as compared to wild type DNAs when probed with the gel-purified 
2.2 kb aroA gene from pPharoA3 and the plasmid vector pBB I 92C (data not shown). The 
isolates yielded two bands of 4 kb and 5.5 kb when probed with aroA sequences whereas 
Kan' 
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Figure 6. lllustration of the events required to yield a single crossover integrant and excision 
of the plasmid to generate a gene replacement mutant. 
51 
wild type aroA yielded a 3 kb band. Furthermore plasmid sequences were identified in each 
isolate when probed with vector pBB l 92C sequences. These results are consistent with 
integration of the replacement plasmid into the chromo omal aroA gene. No mutants 
resu lting from double crossover events were isolated. 
To screen for mutants that have undergone a second crossover event the EI l isolate, a 
single crossover mutant unable to grow in defined media, was passed at the permissive 
temperature of 30°C fo r several generations. Growth at thi s temperature will yield one of two 
events; I ) the plasmid may resolve out of the chromosome yielding a wild type genotype, or 
2) an allelic exchange event may occur yielding a mutated chromosomal aroA gene. 
Furthermore, resolved plasmid is cured from the when the organism is grown without 
antibiotic selection at the permiss ive temperature. Each passage was struck onto a master 
plate of Columbia agar without antibiotic and grown overnight at 40°C to stabilize remain ing 
single crossover integrants and to generate iso lated co lonies for screening. Isolated colonies 
were scored for ampicillin and kanamycin resistance. 
Four iso lates were identified that were ampicillin resistant, kanamycin sensitive, and 
failed to grow in Wessman defined medium. Southern blot analysis of HindHI digested 
genomic ON As of the fo ur isolates and wi ld-type ADC-01 71 revealed that three iso lates 
contained vector sequences and the ~aroA-ampr cassette when probed with radiolabeled 
pBB I 92C. T his was consistent with the molecular profile of a single crossover product (data 
not shown). Also Southern blotting confirmed the presence of the kanamycin resistance gene 
in the chromosome which implied that a mutation had occurred in the kanamycin gene 
resulting in the antibiotic sensitive phenotype. The fourth isolate, F9.80, revealed that no 
vector sequences were retained in its genome when probed with radio labeled pBB l 92C and 
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was further ana lyzed as a putative aroA mutant Southern blot anal ysis (Figure 7) comparing 
HindlII-digested genomic DNA o f wild-type P. haemoz1·tica ADC-D 17 1 to the putative 
aroA mutant F9.80 using radiolabeled ST I aroA confirmed earli er Southern blot data 
demonstrating a 2.0 kb increase in molecular size of aroA containing fragment in the mutant 
as compared to wild-type aroA. The increase in size is equal to the P-lactamase gene 
inserted into the de letion site of aroA. Furthermore, radiolabeled plasmid pBB I 92C 
confirmed that no vector sequences were present in the genome of F9.80. Linearized plasmid 
pBB I 92C!:laroA-ampR was used as a control. Finally, the 200 bp NdeI-Bs tEII aroA deleted 
fragment was radiolabeled and hybridized to wildtype, F9.80 DNAs, and linearized 
pBB I 92C!:laroA-ampR replacement plasmid. The mutant DNA failed to hybridize to the 200 
bp fragment whereas wildtype DNA did so. The events that transpired to produce the aroA 
mutant are depicted in Figure 6. 
To confirm tryptophan auxotrophy, aroA mutant F9.80 was inoculated into Columbia 
broth conta ining ampicillin and into Wessman defined media w ith or without tryptophan. 
Growth in the Columbia broth and in the Wessman broth supplemented with tryptophan were 
comparable, but F9.80 failed to grow in Wessman broth Jacking tryptophan. This, taken 
together w ith Southern blot data demonstrated that F9.80 was an aroA mutant. 
Finally, it was important to confirm that F9.80 was P. haemolytica ST2. Therefore, the 
mutant was struck onto blood agar plates containing 5% sheep erythrocytes for observation 
of P-hemolysis (34). After overnight incubation at 37°C, noticeable c learing had occurred 
under the mucoid co lonies showing erythrocyte lysis consistent with P. haemoly tica 
morphology. Furthermore, iso lates were chosen from these plates fo r confirmation of 
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Figure 7. Southern hybridization of genomic DNA from the parental P. haemolytica NADC-D 171 ST 2 (lanes I), the aroA mutant 
(lanes 2), and plasmid pBB I 92CDaroA.ampr (lanes 3). One microgram of parental and mutant DNA were digested with lli11dlll 
whereas 15 ng of plasmid DNA was digested with Styl to linearize it. (A) Probed with P. haemoly tica STI aroA; (8) probed with 
pBBl 92C; (C) Probed wi th Ndel and BstEll double digested and isolated 200bp aroA fragment. A slight band in lane 3 of panel 
(C) indicates that the probe may have been contaminated with some vector sequences. 
54 
serotype. The rapid plate agglutination assay using ST I and ST 2 speci fi c antiserum was 
also confirmatory; no agglutination was observed with ST! antiserum, but marked 
agglutination was observed using ST2 antiserum demonstrating that F9.80 was P. 
lzaemolytica ST2 (36). 
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CONCLUSIONS 
Summary 
Pneumonic pasteu rellos is is a devastating disease affecting a wide variety of an imals. The 
principal etiolog ic agents in cattle and sheep are P. haemoz\•tica ST I and ST2, respecti vely. 
To effectively control these pathogens, vaccines that induce a strong immunity to the 
organism are desirab le. One attracti ve means of achieving thi s goal is through construction of 
attenuated live vaccines. The aromatic amino acid biosynthetic pathway of prokaryotes yields 
the amino acids tyrosine, tryptophan, and phenylalanine. Many pathogenic bacteri a defective 
in this pathway have been shown to be attenuated w ith a diminished abi lity to replicate in 
\'ivo. 
In this study we have cloned and sequenced the P. haemozvrica ST2 aroA gene and 
demonstrated that it has 99 .1 % identity with P. haemo~\ ·tica ST I aroA. Furthermore, we have 
constructed a P. haemolytica ST2 aroA mutant by allelic exchange and demonstrated it 
required tryptophan for growth in chemically defined media. Previous studies have hown 
that aroA mutants are good attenuated li ve vaccine candidates (2 1, 46, 70, 92). A 
combination of ST I and ST2 vaccines may cross protect against the other P. haemolytica 
(biotype A) important to disease. 
Future Research 
A combined multivalent vaccine consisting of an aroA mutant of P. haemolytica STI and 
ST2, P. multocida A3, and Haemophilus somnus may provide cattle and sheep protection 
from field infections with the wi ld-type of the respect ive organisms better than the existing 
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vaccines. This hypothesis needs to be further investigated in large scale animal studies. We 
wil l be further testing the P. haemo~11tica ST2 aroA mutant in a small scale sheep study to 
determine the efficacy of this mutant as a potential vaccine candidate. 
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APPENDIX A 
WESSMAN DEFINED MINIMAL MEDIA 
For use with Pasteurella haemolytica. P. multocida, and P. ureae. 
Salt solution is mixed in a total volume of 50 ml dH
2
0: 
Citric acid 1.05 g 
K,HPOJ 2. 18 g 
FeSOJ 27.8 mg 
MnSO. 1.6 mg 
pH to 6.5 us ing xN NaOH 
Amino acid so lution is mixed in a tota l vo lume of 400 ml dH20 
Alanine 290 mg 
Arginine 370 mg 
A partic acid 640 mg 
Glutamic acid 2.03 g 
Glycine 180 mg 
Histidine HCI 280 mg 
Isoleuc ine 550 mg 
Leucine 830 mg 
Ly ine HCI 740 mg 
Phenyla lanine 450 mg 
Praline 960 mg 
Valine 650 mg 
Threonine 440 mg 
Tyrosine 150 mg 
Mix the Salt solution and the Amino acid solution and re-pH to 7.4 using Na,C0 1 
Add to the resulting so lution: 
Cyste ine HCI 0. 16 g 
MgSO. 2.23 g 
ca·2 Pantothenate 0.0025 g 
Nicotinamide 0.005 g 
Thiamine HCI 0.000 I g 
pH to 7.4 using Na,C01 and add the fo llowing to the resulting so lution: 
Galactose 5 g 
Glucose 0.5 g 
Filter sterilize and store at 4°C 
58 
APPENDIX B 
GENBANK DEPOSIT OF P. HAEMOLYTICA ST2 AROA NUCLEOTIDE AND 
AMINO ACID SEQUENCES. 
LOCUS PHU89948 1579 bp DNA BCT 16-MAR-1997 
DEFINITION Pasteurella haemolytica serotype 2 aroA gene, 
complete eds . 
ACCESSION U89948 
NID g1890138 
KEYWORDS 
SOURCE 
ORGANISM 
REFERENCE 
AUTHORS 
TITLE 
JOURNAL 
REFERENCE 
AUTHORS 
TITLE 
JOURNAL 
FEATURES 
source 
gene 
CDS 
Pasteurella haemolytica. 
Pas t eurella haemolytica 
Eubacteria; Proteobacteria ; gamma subdivision ; 
Pasteurellaceae ; Pasteurella . 
1 (bases 1 to 1579) 
Hellrung,D . J . , Tatum,F . M. and 
Molecular Cloning, Nucleotide 
Construction of a Pasteurella 
2 aroA Mutant 
Unpublished 
2 (bases 1 to 15 7 9 ) 
Briggs,R . E. 
Sequencing, and 
haemolytica Serotype 
Hellrung , D. J . , Tatum,F . M. and Briggs,R . E . 
Direct Submission 
Submitted (18- FEB-1997) RDNRU, National Animal 
Disease Center , Agricultural Research Service, 
United States Department of Agriculture , 23 00 
Dayton Ave . , Ames , IA 50010 , USA 
Location/Qualifiers 
1. . 1579 
/organism= "Pasteurella haemolytica" 
/strain= "NADC-D171 " 
/serotype= " 2 " 
/db_xref= " taxon : 746 " 
160 .. 1458 
/gene= "aroA " 
160 .. 1458 
/gene= "aroA " 
/codon_ start=l 
/produc t="AroA " 
/db_xref="PID : g1890139" 
/transl table=ll 
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/ translation= "MEKLTLTPISRVEGEINLPGSKSLSNRALLLAALATGTTQVT 
NLLDSDDIRHMLNALKALGVKYELSDDKTVCVVEGI GGAFKVQNGLSLFLGN 
AGTAMRPLAAALCLKGAETAQI ILTGEPRMKERPIKHLVDALRQVGAEVQYL 
ENEGYPPLAISNSGLQGGKVQIDGS ISSQFLTALLMSAPLAES DMEIEIIGD 
LVSKPYIDI TLSMMNDFGITVENRDYKTFLVKGKQGYVAPQGNYLVEGDASS 
ASYFLASGAIKGKVKVTGIGKKS I QGDRLFADVLEKMGAKITWGEDFIQAEQ 
SPLKGVDMDMNHIPDAAMTIATTALFAEGETVIRNIYNWRVKETDRLTAMAT 
ELRKVGAEVEEGEDFIRIQPLALENFQHAEIETYNDHRMAMCFSLI ALSNTE 
VTILDPNCTAKTFPTYFRELEKLSVR " 
BASE COUNT 
ORIGIN 
488 a 30 1 c 364 g 42 6 t 
1 gtgattgt t c gctcgatagc aggttatgga atgccgaatc atttacgcat tagtatcggt 
61 ttaccgcaag aaaacgagag attttttact gccttattga aagtgttagc ttaacaagcg 
121 gttacctttt atgaaaattt tacaaattta aagagaaaaa tggaaaaact aactttaacc 
181 ccgatttccc gagtagaagg cgagatcaat ttacctggtt ctaaaagcct gtctaaccga 
241 gcctta t tat t agccgcctt agccaccggt acgactcaag tgaccaattt attagatagt 
301 gatgatattc gacatatgct caatgcctta aaagcgttag gcgtgaaata tgagctatcg 
361 gacgataa aa ccgtctgtgt agttgaaggg attggtggag cttttaaggt tcaaaacggc 
421 ttatcactgt ttctcggcaa tgcaggcacg gcaatgcgac cact t gcagc agcattgtgt 
481 ttaaaagggg cggaaacagc tcaaatcatt cttaccggtg agccaagaat gaaagaacgc 
541 ccgattaaac atttagtcga tgctttacgc caagtagggg cagaggtaca gtatttagaa 
601 aatga a ggct atccgccgtt a gcaattagc aata gcggtt tgcaaggtgg aaaagtgcaa 
661 attgacggct cgatttccag ccaatttcta accgcat t gc tgatgtctgc cccattagcg 
721 gaaagcgata tggaaattga gattatcggt gatctggtat caaaacctta tattgatatt 
781 accctttcga tgat gaacga t t t t ggt att acggttgaaa atcgagatta caaaaccttt 
841 ttagttaaag gtaaacaagg ctatgttgct ccacaaggta attatttggt ggagggagat 
901 gcctcttctg cctcttattt cttagcctcc ggtgcgatta aaggcaaggt aaaagtaacg 
961 ggcattggta aaaaatcgat ccaaggcgac cgcttgtttg ccgatgtgtt ggaaaaaatg 
1021 g gg g c a aaaa tcacttgggg a gaggatttt attcaagccg agcaatcccc gctaaaaggc 
1081 gtagatatgg atatgaatca tattcctgat gcggcaatga cgattgcaac aaccgcttta 
1141 tttgccga ag gagaa acagt t atccgcaat atttataact ggcgggtaaa agaaaccgac 
1201 cgc t tgacag caatggcaac cgaattgcgt aaagtcgggg cagaggtaga agaaggggaa 
1261 gattttattc ggattcaacc gcttgcgtta gaaaacttcc agcacgctga aattgaaacc 
132 1 tataacgatc accgt atggc aatgtgtttt tcattaattg cgttatcgaa tacagaagtg 
1381 acgatcttag atccaaattg taccgc t aaa acgttcccga cttactttag ggagttggaa 
1441 aaattatcgg tcagataaaa gtaaaaaagg at t cagaaaa ctgaatcctt tttacgtttt 
1501 attgtggcag actaagccca accgctaagc cgaattctgc agatatccat cacactggcg 
1561 gccgctcgag catgcatct 
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